<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Beta2‐agonists for exercise‐induced asthma - Bonini, M - 2013 | Cochrane Library</title> <meta content="Beta2‐agonists for exercise‐induced asthma - Bonini, M - 2013 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003564.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Beta2‐agonists for exercise‐induced asthma - Bonini, M - 2013 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003564.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003564.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Beta&lt;sub&gt;2&lt;/sub&gt;‐agonists for exercise‐induced asthma" name="citation_title"/> <meta content="Matteo Bonini" name="citation_author"/> <meta content="matte.bonini@gmail.com" name="citation_author_email"/> <meta content="Corrado Di Mambro" name="citation_author"/> <meta content="Children's Hospital &quot;Bambino Gesù&quot;" name="citation_author_institution"/> <meta content="Moises A Calderon" name="citation_author"/> <meta content="National Heart and Lung Institute, Imperial College London and Royal Brompton Hospital" name="citation_author_institution"/> <meta content="Enrico Compalati" name="citation_author"/> <meta content="University of Genoa" name="citation_author_institution"/> <meta content="Holger Schünemann" name="citation_author"/> <meta content="McMaster University" name="citation_author_institution"/> <meta content="Stephen Durham" name="citation_author"/> <meta content="National Heart and Lung Institute, Imperial College London and Royal Brompton Hospital" name="citation_author_institution"/> <meta content="Giorgio W Canonica" name="citation_author"/> <meta content="University of Genoa" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD003564.pub3" name="citation_doi"/> <meta content="2013" name="citation_date"/> <meta content="2013/10/02" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003564.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003564.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003564.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Inhalation; Adrenergic beta‐2 Receptor Antagonists [*administration &amp; dosage]; Asthma, Exercise‐Induced [*drug therapy]; Bronchoconstriction; Bronchodilator Agents [*administration &amp; dosage]; Forced Expiratory Volume [drug effects]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003564.pub3&amp;doi=10.1002/14651858.CD003564.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003564.pub3&amp;doi=10.1002/14651858.CD003564.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003564.pub3&amp;doi=10.1002/14651858.CD003564.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003564.pub3&amp;doi=10.1002/14651858.CD003564.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003564.pub3&amp;doi=10.1002/14651858.CD003564.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003564.pub3&amp;doi=10.1002/14651858.CD003564.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003564.pub3&amp;doi=10.1002/14651858.CD003564.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003564.pub3&amp;doi=10.1002/14651858.CD003564.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003564.pub3&amp;doi=10.1002/14651858.CD003564.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003564.pub3&amp;doi=10.1002/14651858.CD003564.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003564.pub3&amp;doi=10.1002/14651858.CD003564.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003564.pub3&amp;doi=10.1002/14651858.CD003564.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003564.pub3&amp;doi=10.1002/14651858.CD003564.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003564.pub3&amp;doi=10.1002/14651858.CD003564.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003564.pub3&amp;doi=10.1002/14651858.CD003564.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003564.pub3&amp;doi=10.1002/14651858.CD003564.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003564.pub3&amp;doi=10.1002/14651858.CD003564.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003564.pub3&amp;doi=10.1002/14651858.CD003564.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003564.pub3&amp;doi=10.1002/14651858.CD003564.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003564.pub3&amp;doi=10.1002/14651858.CD003564.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003564.pub3&amp;doi=10.1002/14651858.CD003564.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003564.pub3&amp;doi=10.1002/14651858.CD003564.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003564.pub3&amp;doi=10.1002/14651858.CD003564.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="IYhCEbRn";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003564\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003564\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003564\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003564\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003564.pub3",title:"Beta\u003csub\u003e2\u003c/sub\u003e\\u2010agonists for exercise\\u2010induced asthma",firstPublishedDate:"Oct 2, 2013 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=IYhCEbRn&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003564.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003564.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003564.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003564.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003564.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003564.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003564.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003564.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003564.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003564.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2897 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003564.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003564.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003564.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003564.pub3/full#CD003564-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003564.pub3/full#CD003564-sec-0067"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003564.pub3/full#CD003564-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003564.pub3/full#CD003564-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003564.pub3/full#CD003564-sec-0017"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003564.pub3/full#CD003564-sec-0018"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003564.pub3/full#CD003564-sec-0040"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003564.pub3/full#CD003564-sec-0061"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003564.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003564.pub3/appendices#CD003564-sec-0072"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003564.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003564.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/table_n/CD003564StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/table_n/CD003564StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003564.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003564.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003564.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003564.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003564.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003564.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2013 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Beta<sub>2</sub>‐agonists for exercise‐induced asthma</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003564.pub3/information#CD003564-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Matteo Bonini</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003564.pub3/information#CD003564-cr-0003">Corrado Di Mambro</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003564.pub3/information#CD003564-cr-0004">Moises A Calderon</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003564.pub3/information#CD003564-cr-0005">Enrico Compalati</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003564.pub3/information#CD003564-cr-0006">Holger Schünemann</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003564.pub3/information#CD003564-cr-0007">Stephen Durham</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003564.pub3/information#CD003564-cr-0008">Giorgio W Canonica</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/information/en#CD003564-sec-0082">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 02 October 2013 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003564.pub3">https://doi.org/10.1002/14651858.CD003564.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003564-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003564-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003564-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003564-abs-0005">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003564-abs-0001" lang="en"> <section id="CD003564-sec-0001"> <h3 class="title" id="CD003564-sec-0001">Background</h3> <p>It is well known that physical exercise can trigger asthma symptoms and can induce bronchial obstruction in people without clinical asthma. International guidelines on asthma management recommend the use of beta<sub>2</sub>‐agonists at any stage of the disease. At present, however, no consensus has been reached about the efficacy and safety of beta<sub>2</sub>‐agonists in the pretreatment of exercise‐induced asthma and exercise‐induced bronchoconstriction. For the purpose of the present review, both of these conditions are referred to by the acronymous EIA, independently from the presence of an underlying chronic clinical disease. </p> </section> <section id="CD003564-sec-0002"> <h3 class="title" id="CD003564-sec-0002">Objectives</h3> <p>To assess the effects of inhaled short‐ and long‐acting beta<sub>2</sub>‐agonists, compared with placebo, in the pretreatment of children and adults with exercise‐induced asthma (or exercise‐induced bronchoconstriction). </p> </section> <section id="CD003564-sec-0003"> <h3 class="title" id="CD003564-sec-0003">Search methods</h3> <p>Trials were identified by electronic searching of the Cochrane Airways Group Specialised Register of Trials and by handsearching of respiratory journals and meetings. Searches are current as of August 2013. </p> </section> <section id="CD003564-sec-0004"> <h3 class="title" id="CD003564-sec-0004">Selection criteria</h3> <p>We included randomised, double‐blind, placebo‐controlled trials of any study design, published in full text, that assessed the effects of inhaled beta<sub>2</sub>‐agonists on EIA in adults and children. We excluded studies that did not clearly state diagnostic criteria for EIA. </p> </section> <section id="CD003564-sec-0005"> <h3 class="title" id="CD003564-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures as expected by The Cochrane Collaboration.</p> </section> <section id="CD003564-sec-0006"> <h3 class="title" id="CD003564-sec-0006">Main results</h3> <p>We included 53 trials consisting of 1139 participants. Forty‐eight studies used a cross‐over design, and five were performed in accordance with a parallel‐group design. Forty‐five studies addressed the effect of a single beta<sub>2</sub>‐agonist administration, and eight focused on long‐term treatment. We addressed these two different intervention regimens as different comparisons. </p> <p>Among primary outcomes for short‐term administration, data on maximum fall in forced expiratory volume in 1 second (FEV<sub>1</sub>) showed a significant protective effect for both short‐acting beta‐agonists (SABA) and long‐acting beta‐agonists (LABA) compared with placebo, with a mean difference of ‐17.67% (95% confidence interval (CI) ‐19.51% to ‐15.84%, P = 0.00001, 799 participants from 72 studies). The subgroup analysis of studies performed in adults compared with those performed in children showed high heterogeneity confined to children, despite the comparable mean bronchoprotective effect. </p> <p>Secondary outcomes on other pulmonary function parameters confirmed a more positive and protective effect of beta<sub>2</sub>‐agonists on EIA compared with placebo. Occurrence of side effects was not significantly different between beta<sub>2</sub>‐agonists and placebo. </p> <p>Overall evaluation of the included long‐term studies suggests a beta<sub>2</sub>‐agonist bronchoprotective effect for the first dose of treatment. However, long‐term use of both SABA and LABA induced the onset of tolerance and decreased the duration of drug effect, even after a short treatment period. </p> </section> <section id="CD003564-sec-0007"> <h3 class="title" id="CD003564-sec-0007">Authors' conclusions</h3> <p>Evidence of low to moderate quality shows that beta<sub>2</sub>‐agonists, both SABA and LABA, when administered in a single dose, are effective and safe in preventing EIA. </p> <p>Long‐term regular administration of inhaled beta<sub>2</sub>‐agonists induces tolerance and lacks sufficient safety data. This finding appears to be of particular clinical relevance in view of the potential for prolonged regular use of beta<sub>2</sub>‐agonists as monotherapy in the pretreatment of EIA, despite the warnings of drug agencies (FDA, EMA) regarding LABA. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003564-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003564-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003564-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003564-abs-0006">فارسی</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003564-abs-0003" lang="en"> <h3>Asthma reliever inhalers (beta2‐agonists) used for exercise‐induced asthma and exercise‐induced bronchoconstriction </h3> <p><b>Review question</b> </p> <p>Physical exercise may trigger symptoms such as cough, chest tightness and shortness of breath in people with asthma that is not adequately treated (exercise‐induced asthma). Sometimes people who do not have asthma still experience asthma‐like symptoms during exercise; this is called <i>exercise‐induced bronchoconstriction</i> . We looked at both types of people in this review. The treatments we were interested in are called <i>beta<sub>2</sub>‐agonists</i>. These are drugs that are known to open up the airways (small tubes in the lungs), making it easier for people to breathe. Two kinds of beta<sub>2</sub>‐agonists are available: short‐acting (SABA, e.g. salbutamol and terbutaline) and long‐acting (LABA, e.g. formoterol and salmeterol). </p> <p><b>What evidence did we find?</b> </p> <p>We found 53 trials consisting of 1139 participants. Forty‐eight studies used a cross‐over design, which meant that each person in the trial received two or more treatments－one or more active treatments, the beta‐agonist and a placebo in random order. The rest were parallel‐group trials, meaning that people received either the active treatment or a placebo. Most of the studies addressed the effect of a giving a single beta<sub>2</sub>‐agonist treatment before exercise and recorded the effect on lung function following exercise. Only eight focused on longer treatment－longer treatments would be needed to assess whether these treatments were harmful over the longer term. </p> <p><b>Results</b> </p> <p>Studies in which people received a single administration of a beta‐agonist showed that FEV<sub>1</sub> (a measure of lung function) fell significantly less for people taking SABA or LABA compared with placebo (mean difference (MD) ‐17.67%; 95% confidence interval (CI) ‐19.51% to ‐15.84%). Other lung function measures confirmed that beta<sub>2</sub>‐agonists were more beneficial compared with placebo. No significant difference in the number of side effects was noted in people taking SABA or LABA compared with people taking placebo. However, it is unlikely that people would be prescribed an inhaler for a single treatment, so we must consider longer‐term studies to get a true measure of the side effects that inhalers can cause. </p> <p>We found that included longer‐term studies showed that beta<sub>2</sub>‐agonists were helpful in terms of lung function for the first dose of treatment. However, studies that provided longer‐term treatment with SABA or LABA showed that over time, people built up a tolerance to the effects of treatments, and the beneficial effects lasted for shorter periods of time. </p> <p><b>Quality of the evidence</b> </p> <p>Overall, we believe that the evidence was of low to moderate quality.</p> <p><b>Conclusions</b> </p> <p>This review shows that beta<sub>2</sub>‐agonists－both SABA and LABA－when administered in a single dose, are effective and safe in preventing the symptoms of EIA. Longer‐term administration of inhaled beta<sub>2</sub>‐agonists induces tolerance and lacks sufficient safety data. It is important to note that taking LABA without background inhaled steroids is considered unsafe and is not currently recommended in most of the clinical guidelines for asthma. We recommend that more studies are needed to determine whether it is safe to administer inhaled beta<sub>2</sub>‐agonists alone to people who experience asthma symptoms when exercising. </p> <p>This review is current as of August 2013.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003564-sec-0067" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003564-sec-0067"></div> <h3 class="title" id="CD003564-sec-0068">Implications for practice</h3> <section id="CD003564-sec-0068"> <p>Beta<sub>2</sub>‐agonists, both SABA and LABA, when administered in a single dose before exercise is undertaken, are effective and safe in preventing exercise‐induced asthma. Long‐term regular administration of inhaled beta<sub>2</sub>‐agonists induces tolerance and lacks sufficient safety data. This finding appears to be of particular clinical relevance in view of the potential for regular prolonged use of beta<sub>2</sub>‐agonists as monotherapy in the pretreatment of EIA, despite the drug agencies' warning on LABA. </p> </section> <h3 class="title" id="CD003564-sec-0069">Implications for research</h3> <section id="CD003564-sec-0069"> <p>Further research should focus on the following.</p> <p> <ul id="CD003564-list-0006"> <li> <p>Distinguishing between EIA (exercise‐induced bronchoconstriction with asthma) from exercise‐induced bronchoconstriction without coexisting asthma as different phenotypes, in relation to clinical features, pathophysiological mechanisms, patterns of inflammation and response to treatments, including beta<sub>2</sub>‐agonists. </p> </li> <li> <p>Evaluating the potential influence of different genotypes (i.e. beta<sub>2</sub>‐adrenergic receptor polymorphisms) and phenotypes on exercise‐induced bronchoconstriction severity and response to beta<sub>2</sub>‐adrenergic treatment. </p> </li> <li> <p>Better defining response to therapy, not only according to functional parameters, but also on the basis of clinical endpoints (symptoms, disease control and patient‐related outcomes), markers of inflammation and omic approaches. </p> </li> <li> <p>Defining standardised operational procedures (i.e. exercise challenges, diagnostic thresholds, outcome measures) for clinical trials in EIA. </p> </li> <li> <p>Performing additional independent trials to address long‐term beta<sub>2</sub>‐agonist administration in EIA, with special reference to concomitant inhaled corticosteroid treatment, to better assess the risk/benefit ratio between drug efficacy and potential cardiovascular side effects and onset of tolerance. </p> </li> <li> <p>Establishing whether pretreatment of EIA with beta<sub>2</sub>‐agonists may exert, beyond the bronchodilator effect, an anti‐inflammatory action, as suggested by recent findings on the role of mechanical factors in inflammation and airways remodelling. </p> </li> <li> <p>Designing protocols specifically addressed to clarify the potential role of generics and different devices in influencing the efficacy and safety of beta<sub>2</sub>‐agonist prevention of EIA. </p> </li> <li> <p>Developing systematic reviews and meta‐analyses to assess which is the most appropriate and effective treatment strategy, among those available, for prevention of exercise‐induced asthma. </p> </li> </ul> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003564-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003564-sec-0015"></div> <div class="table" id="CD003564-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Beta2‐agonists compared with placebo (single administration) for exercise‐induced asthma</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Beta<sub>2</sub>‐agonists compared with placebo (single administration) for exercise‐induced asthma</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> exercise‐induced asthma <br/> <b>Intervention:</b> beta<sub>2</sub>‐agonists<br/> <b>Comparison:</b> placebo (single administration) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo (single administration)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Beta<sub>2</sub>‐agonists</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maximal percentage fall in FEV<sub>1</sub> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean fall in FEV<sub>1</sub> in the intervention group was MD 17.67 lower (19.51 lower to 15.84 lower)<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>－</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>799<br/> (72 studies)<sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>d,e,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The results in the subgroup of LABA and SABA were similar: MD 15.6 lower (18.29 lower to 12.92 lower) and MD 18.99 lower (21.38 lower to 16.6 lower) in 44 and 28 studies, respectively </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with an FEV<sub>1</sub> fall &gt; 10% </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>843 per 1000 (84.3)%</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 per 1000<br/> (243 to 410) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.08</b> (0.06 to 0.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>773<br/> (19 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>d,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maximal percentage fall in PEF</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean maximal percentage fall in PEF in the intervention group was MD 24.61 lower (37.57 lower to 11.65 lower)<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>－</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92<br/> (14 studies)<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>d,e,g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maximal percentage fall in FEF<sub>25‐75%</sub> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean maximal percentage fall in FEF<sub>25‐75%</sub> in the intervention group was MD 20.75 lower (27.17 lower to 14.32 lower)<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>－</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106<br/> (8 studies)<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>d,e,g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Side effects</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000 (5.0)%</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>42 per 1000<br/> (22 to 77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.83</b> (0.43 to 1.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2165<br/> (55 studies)<sup>h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>e,g,I</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; FEF<sub>25‐75%</sub>: forced expiratory flow 25–75%; FEV1: forced expiratory volume in 1 minute; LABA: long‐acting beta<sub>2</sub>‐agonist; MD: mean difference; OR: odds ratio; peak expiratory flow (PEF); SABA: short‐acting beta<sub>2</sub>‐agonist. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Lower indicates that beta<sub>2</sub>‐agonists are better than placebo. </p> <p><sup>b</sup>In 51 studies that provided data for subgroup analysis, no difference was observed in the maximal percentage fall in FEV<sub>1</sub>, but the heterogeneity of the effect was seen primarily in the paediatric population. </p> <p><sup>c</sup>These represent 72 study arms from 53 studies. </p> <p><sup>d</sup>It is unclear how directly pulmonary function measures relate to what participants feel. </p> <p><sup>e</sup>There was concern about lack of concealment, loss to follow‐up and reporting bias. </p> <p><sup>f</sup>Inconsistency was moderate to high and was explained in part by subgroup analyses of adults and children. </p> <p><sup>g</sup>Small numbers of participants were included with resulting wide confidence intervals. </p> <p><sup>h</sup>These represent 55 study arms rather than studies. </p> <p><sup>i</sup>This represents a mix of outcomes, and not all of them are of equal importance to patients. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003564-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003564-sec-0016"></div> <p>Exercise‐induced asthma (EIA) is the term commonly used to describe the transient increase in airway resistance that follows vigorous exercise (<a href="./references#CD003564-bbs2-0196" title="AndersonSD . Exercise‐induced asthma. In: KayAB editor(s). Allergy and Allergic Disease. Oxford: Blackwell Scientific Publications, 1997:692‐711. ">Anderson 1997</a>). However a recent position paper suggested a preferred definition of exercise‐induced bronchoconstriction (EIB) with or without asthma, depending on the presence of underlying clinical asthma (<a href="./references#CD003564-bbs2-0215" title="WeilerJM ,  AndersonSD ,  RandolphC , BoniniS , CraigTJ , PearlmanDS , et al. Pathogenesis, prevalence, diagnosis, and management of exercise‐induced bronchoconstriction: a practice parameter. Annals of Allergy, Asthma &amp; Immunology2010;105(6 suppl):1‐47. ">Weiler 2010</a>). Despite this new nomenclature, most of the relevant studies were published before these terms were proposed and often do not provide sufficient information to distinguish between the two conditions. We therefore decided to adopt the term <i>exercise‐induced asthma</i> (EIA) throughout the review for the sake of better consistency and clarity. </p> <p>The prevalence of EIA ranges from 5% to 20% in the general population, to even 100% in people with uncontrolled asthma. This huge variability depends not only on the criteria used for diagnosis, but also on the population samples studied. EIA is, in fact, reported to be particularly frequent in children (<a href="./references#CD003564-bbs2-0208" title="RandolphC . Exercise‐induced bronchospasm in children. Clinical Reviews in Allergy &amp; Immunology2008;34(2):205‐16. ">Randolph 2008</a>), in people with rhinitis (<a href="./references#CD003564-bbs2-0200" title="BrozekJL ,  BousquetJ ,  Baena‐CagnaniCE , BoniniS , CanonicaGW , CasaleTB , et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. Journal of Allergy and Clinical Immunology2010;126(3):466‐76. ">Brozek 2010</a>) and in athletes, with percentages varying according to different sport disciplines (<a href="./references#CD003564-bbs2-0201" title="CarlsenKH , AndersonSD , BjermerL , BoniniS , BrusascoV , CanonicaW , et al. Exercise‐induced asthma, respiratory and allergic disorders in elite athletes: epidemiology, mechanisms and diagnosis: part I of the report from the Joint Task Force of the European Respiratory Society (ERS) and the European Academy of Allergy and Clinical Immunology (EAACI) in cooperation with GA2LEN. Allergy2008;63(4):387‐403. ">Carlsen 2008</a>). </p> <p>The diagnosis of EIA is usually made by exercise testing, either in the field or in the laboratory; this second option allows more standardised procedures (<a href="./references#CD003564-bbs2-0210" title="RundellKW , WilberRL , SzmedraL , JenkinsonDM , MayersLB , ImJ . Exercise‐induced asthma screening of elite athletes: field versus laboratory exercise challenge. Medicine &amp; Science in Sports &amp; Exercise2000;32(2):309‐16. ">Rundell 2000</a>). An individual's response to exercise is generally expressed by the maximal percent fall in forced expiratory volume in one second (FEV<sub>1</sub>). The maximal percent fall is considered an expression of severity of EIA and is calculated by subtracting the lowest FEV<sub>1</sub> value from the pre‐exercise value and expressing it as a percentage of the pre‐exercise value. Both European Respiratory Society (ERS) and American Respiratory Society (ATS) recommendations set a fall threshold of 10% as a diagnostic criterion for EIA and a value greater than 30% as a marker of severe bronchial hyperreactivity, particularly if the person is treated with inhaled steroids (<a href="./references#CD003564-bbs2-0214" title="SterkPJ , FabbriLM , QuanjerPH , CockcroftDW , O'ByrnePM , AndersonSD , et al. Airway responsiveness. Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. European Respiratory Journal1993;16(Suppl):53‐83. ">Sterk 1993</a>). Other indirect tests such as eucapnic voluntary hyperpnoea (EVH) and mannitol challenge are usually considered surrogate tests for the diagnosis of EIA because they induce similar pathophysiological changes in the airways (<a href="./references#CD003564-bbs2-0197" title='AndersonSD , BrannanJD . Methods for "indirect" challenge tests including exercise, eucapnic voluntary hyperpnea, and hypertonic aerosols. Clinical Reviews in Allergy &amp; Immunology2003;24(1):27‐54. '>Anderson 2003</a>). </p> <p>The main principle of treating EIA involves reversing the bronchial obstruction induced by exercise with bronchodilators or preventing it with daily use of either controller drugs in people with asthma (<a href="./references#CD003564-bbs2-0204" title="KohMS , TeeA , LassersonTJ , IrvingLB . Inhaled corticosteroids compared to placebo for prevention of exercise induced bronchoconstriction. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD002739.pub3] ">Koh 2007</a>; <a href="./references#CD003564-bbs2-0199" title="BatemanED , HurdSS , BarnesPJ , BousquetJ , DrazenJM , FitzGeraldM , et al. Global strategy for asthma management and prevention: GINA executive summary. European Respiratory Journal2008;31(1):143‐78. ">Bateman 2008</a>) or drugs that inhibit symptoms and improve pulmonary function immediately before exercise. Pretreatment before exercise includes mast cell stabilisers (<a href="./references#CD003564-bbs2-0203" title="KellyKD , SpoonerCH , RoweBH . Nedocromil sodium versus sodium cromoglycate for preventing exercise‐induced bronchoconstriction. Cochrane Database of Systematic Reviews2000, Issue 3. [DOI: 10.1002/14651858.CD002731] ">Kelly 2000</a>; <a href="./references#CD003564-bbs2-0213" title="Spooner CH ,  Spooner GR ,  RoweBH . Mast‐cell stabilising agents to prevent exercise‐induced bronchoconstriction. Cochrane Database of Systematic Reviews2003, Issue 4. [DOI: 10.1002/14651858.CD002307] ">Spooner 2003</a>), leukotriene antagonists (<a href="./references#CD003564-bbs2-0207" title="PeroniDG ,  PescollderunggL ,  SandriM , ChinellatoI , BonerAL , PiacentiniGL . Time‐effect of montelukast on protection against exercise‐induced bronchoconstriction. Respiratory Medicine2011;105(12):1790‐7. ">Peroni 2011</a>), short‐acting beta<sub>2</sub>‐agonists (SABA) and, more recently, long‐acting beta<sub>2</sub>‐agonists (LABA), especially in endurance athletes (<a href="./references#CD003564-bbs2-0212" title="ShapiroGS , YegenU , XiangJ , KottakisJ , Della CioppaG . A randomized, double‐blind, single‐dose, crossover clinical trial of the onset and duration of protection from exercise‐induced bronchoconstriction by formoterol and albuterol. Clinical Therapeutics2002;24(12):2077‐87. ">Shapiro 2002</a>). </p> <p>Both SABA and LABA, administered at standard doses immediately before exercise, have been shown to reduce the fall in FEV<sub>1</sub> by 70% to 80% in most people with EIA (<a href="./references#CD003564-bbs2-0198" title="AndersonSD , CaillaudC , BrannanJD . Beta2‐agonists and exercise‐induced asthma. Clinical Reviews in Allergy &amp; Immunology2006;31(2‐3):163‐80. ">Anderson 2006</a>). The mechanism of this protection is believed to be related to beta<sub>2</sub>‐receptor－induced relaxation of bronchial smooth muscle, which opposes the contractile effects of the various mediators of bronchoconstriction. Protection from EIA is also afforded by beta<sub>2</sub>‐receptor－induced inhibition of mediator release from mast cells. </p> <p>At present, however, no consensus has been reached about the efficacy and safety of beta<sub>2</sub>‐agonists in the pretreatment of EIA. The role of these molecules in preventing EIA was questioned when patients taking beta<sub>2</sub>‐agonists daily reported breakthrough EIA within a dosing period. Several negative findings have been reported regarding the efficacy of daily treatment with beta<sub>2</sub>‐agonists in controlling the severity of bronchoconstriction and recovery from EIA. In fact, in a significant minority of people, EIA is not prevented by beta<sub>2</sub>‐agonists administered at the recommended dose (<a href="./references#CD003564-bbs2-0092" title="AndersonSD , RodwellLT , Du ToitJ , YoungIH . Duration of protection by inhaled salmeterol in exercise‐induced asthma. Chest1991;100(5):1254‐60. ">Anderson 1991</a>; <a href="./references#CD003564-bbs2-0190" title="WeilerJM , NathanRA , RuppNT , KalbergCJ , EmmettA , DorinskyPM . Effect of fluticasone/salmeterol administered via a single device on exercise‐induced bronchospasm in patients with persistent asthma. Annals of Allergy, Asthma &amp; Immunology2005;94(1):65‐72. ">Weiler 2005</a>). Furthermore, it has been reported how daily treatment with beta<sub>2</sub>‐agonists can enhance the severity of EIA (<a href="./references#CD003564-bbs2-0037" title="HancoxRJ , SubbaraoP , KamadaD , WatsonRM , HargreaveFE , InmanMD . Beta2‐agonist tolerance and exercise‐induced bronchospasm. American Journal of Respiratory and Critical Care Medicine2002;165(8):1068‐70. ">Hancox 2002</a>) and decrease the duration of their protective effect, especially for LABA (<a href="./references#CD003564-bbs2-0070" title="RamageL , LipworthBJ , IngramCG , CreeIA , DhillonDP . Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respiratory Medicine1994;88(5):363‐8. ">Ramage 1994</a>). In addition, recovery from EIA after a standard dose of beta<sub>2</sub>‐agonists is slower, and additional doses are often required when SABA or LABA are used daily (<a href="./references#CD003564-bbs2-0037" title="HancoxRJ , SubbaraoP , KamadaD , WatsonRM , HargreaveFE , InmanMD . Beta2‐agonist tolerance and exercise‐induced bronchospasm. American Journal of Respiratory and Critical Care Medicine2002;165(8):1068‐70. ">Hancox 2002</a>). </p> <p>On the other hand, the reported association between administration of LABA, not in combination with inhaled corticosteroids, and increased numbers of severe cardiovascular side effects and sudden deaths (<a href="./references#CD003564-bbs2-0206" title="NelsonHS , WeissST , BleeckerER , YanceySW , DorinskyPM , for the SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest2006;129:15‐26. ">Nelson 2006</a>; <a href="./references#CD003564-bbs2-0211" title="Salpeter SR ,  WallAJ ,  BuckleyNS . Long‐acting beta‐agonists with and without inhaled corticosteroids and catastrophic asthma events. American Journal of Medicine2010;123(4):322‐8. ">Salpeter 2010</a>) induced the U.S. Food and Drug Administration (FDA) to set a "black box" on these drugs, highlighting the urgent need to promote clear studies of pharmacovigilance (<a href="./references#CD003564-bbs2-0205" title="MartinezFD . Safety of long‐acting beta‐agonists－an urgent need to clear the air. New England Journal of Medicine2005;353:2637‐9. ">Martinez 2005</a>). </p> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003564-sec-0017" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003564-sec-0017"></div> <p>To assess the effects of inhaled short‐ and long‐acting beta<sub>2</sub>‐agonists, compared with placebo, in the pretreatment of children and adults with exercise‐induced asthma (or exercise‐induced bronchoconstriction). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003564-sec-0018" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003564-sec-0018"></div> <section id="CD003564-sec-0019"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003564-sec-0020"> <h4 class="title">Types of studies</h4> <p>We included double‐blind, randomised controlled trials (RCTs) of any study design. Data published in abstract form only were excluded. At least one primary outcome of this systematic review had to be reported for a study to be considered eligible. </p> </section> <section id="CD003564-sec-0021"> <h4 class="title">Types of participants</h4> <p>We included children and adults (aged 18 years or older) with a clear history of exercise‐induced asthma and/or a positive response to a standardised exercise challenge, defined according to ERS and ATS guidelines as a fall in FEV<sub>1</sub> ≥ 10%. Studies that did not clearly state criteria for EIA diagnosis were excluded. </p> </section> <section id="CD003564-sec-0022"> <h4 class="title">Types of interventions</h4> <p>Eligible interventions included inhaled beta<sub>2</sub>‐agonists administered, at any dose, as short‐term or long‐term prophylactic treatment before participants underwent a standardised exercise challenge. SABA and LABA had to be administered within a time period before exercise challenge that did not exceed their pharmacological half‐life (arbitrarily set at 1 hour for SABA, and at 12 hours for LABA). For studies with more than one drug arm, only the comparison with placebo was considered. Studies with more than one drug arm that evaluated different beta<sub>2</sub>‐agonist molecules were considered as separate trials. </p> </section> <section id="CD003564-sec-0023"> <h4 class="title">Types of outcome measures</h4> <section id="CD003564-sec-0024"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD003564-list-0001"> <li> <p>Mean max % fall in FEV<sub>1</sub> (100 × (baseline pre‐exercise value － lowest postexercise value)/baseline pre‐exercise value) in people treated with a beta<sub>2</sub>‐agonist versus mean max % fall in FEV<sub>1</sub> in people treated with placebo </p> </li> <li> <p>Mean % protection afforded by beta<sub>2</sub>‐agonists (% protection = 100 × (max % fall FEV<sub>1</sub> placebo － max % fall FEV<sub>1</sub> beta<sub>2</sub>‐agonist)/max % fall FEV<sub>1</sub> placebo) </p> </li> <li> <p>Mean area under the curve (AUC) of time course changes in FEV<sub>1</sub> after exercise in people treated with a beta<sub>2</sub>‐agonist versus mean AUC of time course changes in FEV<sub>1</sub> after exercise in people treated with placebo </p> </li> </ul> </p> </section> <section id="CD003564-sec-0025"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD003564-list-0002"> <li> <p>Number of people with a max % fall in FEV<sub>1</sub> &lt; 10% (complete protection), &lt; 15% and &lt; 20% </p> </li> <li> <p>Changes from baseline in symptom and sign scores</p> </li> <li> <p>Mean max % fall in other pulmonary function parameters (peak expiratory flow (PEF), forced expiratory flow 25–75% (FEF), maximal expiratory flow at 50% (MEF) etc.) </p> </li> <li> <p>Onset of tolerance (considered for long‐term administration studies and in relation to concomitant treatment with inhaled corticosteroids) </p> </li> <li> <p>Outcomes of physical performance</p> </li> <li> <p>Side/adverse effects</p> </li> </ul> </p> </section> </section> </section> <section id="CD003564-sec-0026"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD003564-sec-0027"> <h4 class="title">Electronic searches</h4> <p>Trials were identified using the Cochrane Airways Group Specialised Register of Trials, which is derived from systematic searches of bibliographic databases, including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and CINAHL, as well as handsearching of respiratory journals and meeting abstracts (see <a href="./appendices#CD003564-sec-0073">Appendix 1</a> for additional details). The Register was searched using the terms in <a href="./appendices#CD003564-sec-0079">Appendix 2</a> from the date of inception up to August 2013. No restriction was placed on language of publication. </p> </section> <section id="CD003564-sec-0028"> <h4 class="title">Searching other resources</h4> <p>We screened reference lists of included studies, recent reviews and textbooks for relevant citations. We contacted authors of unpublished or 'in‐progress' studies and selected manufacturers of beta<sub>2</sub>‐agonists to identify additional studies. Furthermore, we searched national and international clinical trial websites (www.clinicalstudyresults.org; www.clinicaltrials.gov; www.fda.gov) for additional trials. Personal contacts with colleagues, collaborators and other trialists working in the field of asthma were at last made to identify further potentially relevant studies. No language or publication restrictions were applied to these searches. </p> </section> </section> <section id="CD003564-sec-0029"> <h3 class="title" id="CD003564-sec-0029">Data collection and analysis</h3> <section id="CD003564-sec-0030"> <h4 class="title">Selection of studies</h4> <p>Titles and abstracts of papers identified in the search were reviewed independently by two review authors (MB, CDM), and articles that appeared to fulfil the inclusion criteria were retrieved. From the full text of these papers, two review authors (MB, EC) independently established whether studies met the inclusion criteria. Studies that did not fulfil all of the inclusion criteria were excluded, and reasons for exclusion were reported. The percentage of agreement was recorded, and any disagreement was solved by consensus. If the two review authors did not reach an agreement, a third review author adjudication (MC) was used to resolve disagreements. In case of further uncertainty, study authors were contacted. Review authors were not blinded to authors, journals, results, etc. </p> </section> <section id="CD003564-sec-0031"> <h4 class="title">Data extraction and management</h4> <p>Data extraction was performed independently by two review authors (MB, EC). Full texts were screened, and bibliographic details, as well as data regarding study design, participants, disease severity, intervention and outcomes, were recorded in predefined forms and entered into <a href="./references#CD003564-bbs2-0209" title="The Cochrane Collaboration. Review Manager (RevMan) Version 5.2. The Cochrane Collaboration, 2012. ">RevMan 5.2</a>. All data, numerical calculations and graphic extrapolations were independently confirmed. We did not deal with missing data. </p> </section> <section id="CD003564-sec-0032"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the risk of bias in included studies as high, low or unclear using The Cochrane Collaboration’s 'Risk of bias' tool (<a href="./references#CD003564-bbs2-0202" title="HigginsJPT , GreenS . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. www.cochranehandbook.org, 2011. ">Higgins 2011</a>) and the following headings. </p> <p> <ul id="CD003564-list-0003"> <li> <p>Random sequence generation (selection bias).</p> </li> <li> <p>Allocation concealment (selection bias).</p> </li> <li> <p>Blinding of participants and personnel (performance bias).</p> </li> <li> <p>Blinding of outcome assessment (detection bias).</p> </li> <li> <p>Incomplete outcome data (attrition bias).</p> </li> <li> <p>Selective reporting (reporting bias).</p> </li> <li> <p>Other bias.</p> </li> </ul> </p> <p>Discussion or third party adjudication was used to resolve disagreements when necessary.</p> </section> <section id="CD003564-sec-0033"> <h4 class="title">Measures of treatment effect</h4> <p>Treatment effects were measured as mean differences (MDs) for continuous outcomes and odds ratios (ORs) for dichotomous outcomes. </p> </section> <section id="CD003564-sec-0034"> <h4 class="title">Unit of analysis issues</h4> <p>Many included studies were of cross‐over design, but many did not report the results of paired <i>t</i>‐tests for continuous outcomes in this review. Some studies provided raw data that allowed a calculation of the correlation between treatment periods on beta<sub>2</sub>‐agonists and placebo on maximum percentage fall in FEV<sub>1</sub> (see <a href="http://www.archie.cochrane.org/sections/documents/viewDiff?documentPK=345500110715515504%26versionPK1=z1305230750042343348840653506005%26versionPK2=z1306101502104628536274520867778#APP-03" target="_blank">Appendix 3</a> for the raw data). We used the average correlation from these studies (0.36) to impute an appropriate standard error for within‐‐participant differences (as described in Section 16.4.6.4 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>; <a href="./references#CD003564-bbs2-0202" title="HigginsJPT , GreenS . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. www.cochranehandbook.org, 2011. ">Higgins 2011</a>). We carried out a meta‐analysis of the mean differences and their standard errors for this outcome using the Generic Inverse Variance method in RevMan 5.2. </p> </section> <section id="CD003564-sec-0035"> <h4 class="title">Dealing with missing data</h4> <p>Missing data on the correlation between results from participants in the cross‐over studies were imputed using the average correlation from studies that reported appropriate raw data. Cross‐over studies provided information on the number of participants in each arm who experienced a given drop in FEV<sub>1</sub>, but not the number of participants whose FEV<sub>1</sub> dropped on both interventions (active treatment and placebo). We were able to calculate marginal odds ratios for these outcomes but could not adjust the standard error to take advantage of the cross‐over design. </p> </section> <section id="CD003564-sec-0036"> <h4 class="title">Assessment of heterogeneity</h4> <p>To assess the level of heterogeneity, the Chi<sup>2</sup> test and the I<sup>2</sup> statistic were used. In establishing the level of heterogeneity, we considered the following rules for interpretation of results (<a href="./references#CD003564-bbs2-0202" title="HigginsJPT , GreenS . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. www.cochranehandbook.org, 2011. ">Higgins 2011</a>). </p> <p> <ul id="CD003564-list-0004"> <li> <p>0 to 30% as low heterogeneity.</p> </li> <li> <p>30% to 60% as moderate heterogeneity worthy of investigation.</p> </li> <li> <p>60% to 90% as severe heterogeneity worthy of understanding.</p> </li> <li> <p>90% to 100% as allowing aggregation only with major caution.</p> </li> </ul> </p> </section> <section id="CD003564-sec-0037"> <h4 class="title">Assessment of reporting biases</h4> <p>Funnel plots were used to investigate the possibility of publication bias.</p> </section> <section id="CD003564-sec-0038"> <h4 class="title">Data synthesis</h4> <p>Data were entered into <a href="./references#CD003564-bbs2-0209" title="The Cochrane Collaboration. Review Manager (RevMan) Version 5.2. The Cochrane Collaboration, 2012. ">RevMan 5.2</a>. For continuous measures, individual and pooled statistics were reported as mean difference (MD) of treatment effect with 95% confidence intervals (95% CIs) using the fixed‐effect model. </p> </section> <section id="CD003564-sec-0039"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Heterogeneity worthy of investigation was examined using the following predefined subgroup analyses. </p> <p> <ul id="CD003564-list-0005"> <li> <p>Type of beta<sub>2</sub>‐agonist (SABA vs LABA). </p> </li> <li> <p>Molecule of beta<sub>2</sub>‐agonist (formoterol vs salmeterol). </p> </li> <li> <p>Age of participants (children vs adults).</p> </li> <li> <p>Concomitant treatments (beta<sub>2</sub>‐agonist monotherapy vs concomitant inhaled corticosteroid treatment). </p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003564-sec-0040" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003564-sec-0040"></div> <section id="CD003564-sec-0041"> <h3 class="title">Description of studies</h3> <p>See:<a href="./references#CD003564-sec-0088" title="">Characteristics of included studies</a>; <a href="./references#CD003564-sec-0089" title="">Characteristics of excluded studies</a>. </p> <section id="CD003564-sec-0042"> <h4 class="title">Results of the search</h4> <p>The search identified 2400 articles, and from these, 289 papers were independently selected by two review authors (k = 0.95) as being of potential interest on the basis of titles and abstracts. After non‐ interventional studies (n = 27) and articles published as abstract only (n = 52) were removed, we retrieved the remaining articles in full text and from these identified 51 studies for inclusion in the meta‐analysis (<a href="#CD003564-fig-0001">Figure 1</a>). Two further articles were added through the cross‐checking reference process. We excluded 158 studies with reasons provided in <a href="./references#CD003564-sec-0089" title="">Characteristics of excluded studies</a>; one study is listed under <a href="./references#CD003564-bbs1-0003" title="">Studies awaiting classification</a> to be considered for inclusion when the review is next updated. </p> <div class="figure" id="CD003564-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD003564-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_n/nCD003564-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD003564-sec-0043"> <h4 class="title">Included studies</h4> <p>Full details can be found in the <a href="./references#CD003564-sec-0088" title="">Characteristics of included studies</a> tables. </p> <section id="CD003564-sec-0044"> <h5 class="title">Study features and design</h5> <p>All 53 included studies were double‐blind, placebo‐controlled, randomised trials. Forty‐eight studies used a cross‐over design, and five were performed in a parallel ‐group design. In the cross‐over studies, washout periods ranged between 1 and 21 days. Nine studies did not mention duration of washout, and in two papers, no washout was performed. The exercise challenges involved treadmill (n = 35), cycle ergometer (n = 13) and free running (n = 5). All challenges were standardised and met recommended testing criteria. Trials were conducted between 1976 and 2010 in 12 different countries: Europe (N = 27), United States/Canada (N = 22) and Australia (N = 4). All articles except one (in Spanish) were written in English. </p> </section> <section id="CD003564-sec-0045"> <h5 class="title">Population</h5> <p>Collectively, included studies reported data on 1139 participants. Population sample size ranged from 10 to 161 participants (55 in a single drug arm of parallel‐group studies and 46 in cross‐over studies－the highest number of enrolled participants). Studies included children and adults (age range 4 to 64 years). A total of 20 studies were performed in children, 18 in adults and 12 in both children and adults. Three papers did not provide sufficient information to allocate people according to age. Nine studies provided only information about ethnicity, and Caucasian was the most represented race. </p> </section> <section id="CD003564-sec-0046"> <h5 class="title">Interventions</h5> <p>Of 53 included studies, 45 addressed beta<sub>2</sub>‐agonist short‐term administration, and eight focused on long‐term treatment. Articles were grouped on the basis of the type of beta<sub>2</sub>‐agonist drugs evaluated: SABA (N = 42; short‐term administration n = 40 and long‐term administration n = 2) and LABA (N = 27, short‐term administration n = 21 and long‐term administration n = 6). Among different beta<sub>2</sub>‐agonists, salbutamol (n = 27), salmeterol (n = 14), formoterol (n = 13) and terbutaline (n = 6) represented the molecules most frequently investigated. Beta<sub>2</sub>‐agonists were delivered through different devices (nebulisers, metered‐dose inhalers (MDIs) and inhalers). </p> <p>Details on dosage and types of beta<sub>2</sub>‐agonist administration are summarised in <a href="#CD003564-tbl-0002">Table 1</a>, together with timing in relation to exercise. </p> <div class="table" id="CD003564-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of study interventions</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention (single dose)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study type (single‐dose test or chronic [duration])</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>When administered before challenge/exercise (min, h)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0001" title="AndersonSD , LambertS , BrannanJD , WoodRJ , KoskelaH , MortonAR , et al. Laboratory protocol for exercise asthma to evaluate salbutamol given by two devices. Medicine &amp; Science in Sports &amp; Exercise2001;33(6):893‐900. ">Anderson 2001 Salb Disk</a>; </p> <p><a href="./references#CD003564-bbs2-0002" title="AndersonSD , LambertS , BrannanJD , WoodRJ , KoskelaH , MortonAR , et al. Laboratory protocol for exercise asthma to evaluate salbutamol given by two devices. Medicine &amp; Science in Sports &amp; Exercise2001;33(6):893‐900. ">Anderson 2001 Salb MDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol diskus 200 mcg</p> <p>Salbutamol MDI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 min</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0003" title="BlakeK , PearlmanDS , ScottC , WangY , StahlE , ArledgeT . Prevention of exercise‐induced bronchospasm in pediatric asthma patients: a comparison of salmeterol powder with albuterol. Annals of Allergy, Asthma &amp; Immunology1999;82(2):205‐11. ">Blake 1999 Salb 180</a> </p> <p><a href="./references#CD003564-bbs2-0004" title="BlakeK , PearlmanDS , ScottC , WangY , StahlE , ArledgeT . Prevention of exercise‐induced bronchospasm in pediatric asthma patients: a comparison of salmeterol powder with albuterol. Annals of Allergy, Asthma &amp; Immunology1999;82(2):205‐11. ">Blake 1999 Salm 25</a> </p> <p><a href="./references#CD003564-bbs2-0005" title="BlakeK , PearlmanDS , ScottC , WangY , StahlE , ArledgeT . Prevention of exercise‐induced bronchospasm in pediatric asthma patients: a comparison of salmeterol powder with albuterol. Annals of Allergy, Asthma &amp; Immunology1999;82(2):205‐11. ">Blake 1999 Salm 50</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Albuterol 180 mcg</p> <p>Salmeterol diskus 25 mcg</p> <p>Salmeterol diskus 50 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 min, 5 h 30, 11 h 30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0007" title="BonerAL , SpeziaE , PiovesanP , ChioccaE , MaiocchiG . Inhaled formoterol in the prevention of exercise‐induced bronchoconstriction in asthmatic children. American Journal of Respiratory and Critical Care Medicine1994;149(4):935‐9. ">Boner 1994 Salb 200</a> </p> <p><a href="./references#CD003564-bbs2-0006" title="BonerAL , SpeziaE , PiovesanP , ChioccaE , MaiocchiG . Inhaled formoterol in the prevention of exercise‐induced bronchoconstriction in asthmatic children. American Journal of Respiratory and Critical Care Medicine1994;149(4):935‐9. ">Boner 1994 Form 12</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol 200 mcg</p> <p>Formoterol 12 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 h, 12 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0008" title="BouletLP , TurcotteH , TenninaS . Comparative efficacy of salbutamol, ipratropium, and cromoglycate in the prevention of bronchospasm induced by exercise and hyperosmolar challenges. Journal of Allergy and Clinical Immunology1989;83(5):882‐7. ">Boulet 1989 Salb</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol 200 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 min</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0009" title="BronskyEA , SpectorSL , PearlmanDS , JustusSE , BishopAL . Albuterol aerosol versus albuterol Rotacaps in exercise‐induced bronchospasm in children. Journal of Asthma1995;32(3):207‐14. ">Bronski 1995 Salb MDI</a> </p> <p><a href="./references#CD003564-bbs2-0010" title="BronskyEA , SpectorSL , PearlmanDS , JustusSE , BishopAL . Albuterol aerosol versus albuterol Rotacaps in exercise‐induced bronchospasm in children. Journal of Asthma1995;32(3):207‐14. ">Bronski 1995 Salb Pwd</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Albuterol MDI 180 mcg</p> <p>Albuterol rotacaps 200 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 min</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0011" title="BronskyEA , PearlmanDS , PobinerBF , ScottC , WangY , StahlE . Prevention of exercise‐induced bronchospasm in pediatric asthma patients: a comparison of two salmeterol powder delivery devices. Pediatrics1999;104:501‐6. ">Bronski 1999 Salm Disk</a> </p> <p><a href="./references#CD003564-bbs2-0012" title="BronskyEA , PearlmanDS , PobinerBF , ScottC , WangY , StahlE . Prevention of exercise‐induced bronchospasm in pediatric asthma patients: a comparison of two salmeterol powder delivery devices. Pediatrics1999;104:501‐6. ">Bronski 1999 Salm Diskhal</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmetrol discus 50 mcg</p> <p>Salmeterol diskhaler 50 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 min, 5 h 30, 11 h 30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0015" title="BronskyEA , YegenU , YehCM , LarsenLV , Della CioppaG . Formoterol provides long‐lasting protection against exercise‐induced bronchospasm. Annals of Allergy, Asthma &amp; Immunology2002;89(4):407‐12. ">Bronski 2002 Salb</a> </p> <p><a href="./references#CD003564-bbs2-0013" title="BronskyEA , YegenU , YehCM , LarsenLV , Della CioppaG . Formoterol provides long‐lasting protection against exercise‐induced bronchospasm. Annals of Allergy, Asthma &amp; Immunology2002;89(4):407‐12. ">Bronski 2002 Form 12</a> </p> <p><a href="./references#CD003564-bbs2-0014" title="BronskyEA , YegenU , YehCM , LarsenLV , Della CioppaG . Formoterol provides long‐lasting protection against exercise‐induced bronchospasm. Annals of Allergy, Asthma &amp; Immunology2002;89(4):407‐12. ">Bronski 2002 Form 24</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Albuterol 180 mcg</p> <p>Formoterol 12 mcg</p> <p>Formoterol 24 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 min, 4 h, 8 h, 12 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0016" title="CarlsenKH , RoksundO , OlsholtK , NjåF , LeegaardJ , BrattenG . Overnight protection by inhaled salmeterol on exercise‐induced asthma in children. European Respiratory Journal1995;8(11):1852‐5. ">Carlsen 1995 Salm 25</a> </p> <p><a href="./references#CD003564-bbs2-0017" title="CarlsenKH , RoksundO , OlsholtK , NjåF , LeegaardJ , BrattenG . Overnight protection by inhaled salmeterol on exercise‐induced asthma in children. European Respiratory Journal1995;8(11):1852‐5. ">Carlsen 1995 Salm 50</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmeterol diskhaler 25 mcg</p> <p>Salmeterol diskhaler 50 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10‐12 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0019" title="CavagniG , CaffarelliC , ManniPL , StapaneI , PretiPAM , CantiniL . Salbutamol administered through a new spacer device to prevent exercise‐induced asthma. Advanced Therapy1993;10(5):207‐16. ">Cavagni 1993 Salb MDI</a> </p> <p><a href="./references#CD003564-bbs2-0018" title="CavagniG , CaffarelliC , ManniPL , StapaneI , PretiPAM , CantiniL . Salbutamol administered through a new spacer device to prevent exercise‐induced asthma. Advanced Therapy1993;10(5):207‐16. ">Cavagni 1993 Salb Jet</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol MDI 200 mcg</p> <p>Salbutamol jet disposable 200 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 min</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0020" title="ClarkePS , RatowskyDA . Effect of fenoterol hydrobromide and sodium cromoglycate individually and in combination on postexercise asthma. Annals of Allergy1990;64:187‐90. ">Clarke 1990 Fen</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fenoterol 100 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 min</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0022" title="DaugbjergP , NielsenKG , SkovM , BisgaardH . Duration of action of formoterol and salbutamol dry‐powder inhalation in prevention of exercise‐induced asthma in children. Acta Paediatrica1996;85(6):684‐7. ">Daugbjerg 1996 Salb</a> </p> <p><a href="./references#CD003564-bbs2-0021" title="DaugbjergP , NielsenKG , SkovM , BisgaardH . Duration of action of formoterol and salbutamol dry‐powder inhalation in prevention of exercise‐induced asthma in children. Acta Paediatrica1996;85(6):684‐7. ">Daugbjerg 1996 Form 12</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol 400 mcg</p> <p>Formoterol 12 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 h, 12 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0023" title="DebelicM , HertelG , KonigJ . Double‐blind crossover study comparing sodium cromoglycate, reproterol, reproterol plus sodium cromoglycate, and placebo in exercise‐induced asthma. Annals of Allergy1988;61(1):25‐9. ">Debelic 1988 Reproterol</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reproterol 1 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 min</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0024" title="deBenedictisFM , TuteriG , PazzelliP , NiccoliA , MezzettiD , VaccaroR . Salmeterol in exercise‐induced bronchoconstriction in asthmatic children: comparison of two doses. European Respiratory Journal1996;9(10):2099‐103. ">DeBenedictis 1996 Salm 25</a> </p> <p><a href="./references#CD003564-bbs2-0025" title="DeBenedictisFM , TuteriG , PazzelliP , NiccoliA , MezzettiD , VaccaroR . Salmeterol in exercise‐induced bronchoconstriction in asthmatic children: comparison of two doses. European Respiratory Journal1996;9(10):2099‐103. ">DeBenedictis 1996 Salm 50</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmeterol 25 mcg</p> <p>Salmeterol 50 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 h, 2 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0026" title="DeBenedictisFM , TuteriG , PazzelliP , SolinasLF , NiccoliA , ParenteC . Combination drug therapy for the prevention of exercise‐induced bronchoconstriction in children. Annals of Allergy, Asthma &amp; Immunology1998;80(4):352‐6. ">DeBenedictis 1998 Salb</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol 200 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 min</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0028" title="DelColG , SpeziaE , RichelliC , PiovesanP , CantiniL , BonerAL . Assessment of a new space device (Jet) for use with inhaled beta2‐agonists in children with exercise‐induced asthma. Pediatric Allergy and Immunology1993;7(2):119‐26. ">Del Col 1993 Salb MDI</a> </p> <p><a href="./references#CD003564-bbs2-0027" title="DelColG , SpeziaE , RichelliC , PiovesanP , CantiniL , BonerAL . Assessment of a new space device (Jet) for use with inhaled beta2‐agonists in children with exercise‐induced asthma. Pediatric Allergy and Immunology1993;7(2):119‐26. ">Del Col 1993 Salb Jet</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol MDI 200 mcg</p> <p>Salbutamol jet device 200 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 min</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0029" title="Dinh XuanAT , LebeauC , RocheR , FerriereA , ChaussainM . Inhaled terbutaline administered via a spacer fully prevents exercise‐induced asthma in young asthmatic subjects: a double‐blind, randomized, placebo‐controlled study. Journal of International Medical Research1989;17(6):506‐13. ">Dinh Xuan 1989 Terb</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terbutaline 500 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 min</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0030" title="EgglestonPA , BeasleyPP . Bronchodilation and inhibition of induced asthma by adrenergic agonists. Clinical Pharmacology &amp; Therapeutics1981;29(4):505‐510. ">Egglestone 1981 Terb 250</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terbutaline 250 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0031" title="FerrariM , BalestreriF , BaratieriS , BiasinC , OldaniV , Lo CascioV . Evidence of the rapid protective effect of formoterol dry‐powder inhalation against exercise‐induced bronchospasm in athletes with asthma. Respiration2000;67(5):510‐3. ">Ferrari 2000 Form 12</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Formoterol 12 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 min, 4 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0032" title="GarciaR , GuerraP , FeoF , GalindoPA , GómezE , BorjaJ , et al. Tachyphylaxis following regular use of formoterol in exercise‐induced bronchospasm. Journal of Investigational Allergology and Clinical Immunology2001;11(3):176‐82. ">Garcia 2001 Form 12</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Formoterol 12 mcg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term (4 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 min, 12 h at days 1, 14 and 28</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0033" title="GreenCP , PriceJF . Prevention of exercise induced asthma by inhaled salmeterol xinafoate. Archives of Disease in Childhood1992;67(8):1014‐7. ">Green 1992 Salm 50</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmeterol 50 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 h, 5 h, 9 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0036" title="GronnerodTA , vonBergA , SchwabeG , SolimanS . Formoterol via Turbuhaler gave better protection than terbutaline against repeated exercise challenge for up to 12 hours in children and adolescents. Respiratory Medicine2000;94(7):661‐7. ">Gronnerod 2000 Terb 500</a> </p> <p><a href="./references#CD003564-bbs2-0035" title="GronnerodTA , vonBergA , SchwabeG , SolimanS . Formoterol via Turbuhaler gave better protection than terbutaline against repeated exercise challenge for up to 12 hours in children and adolescents. Respiratory Medicine2000;94(7):661‐7. ">Gronnerod 2000 Form 9</a> </p> <p><a href="./references#CD003564-bbs2-0034" title="GronnerodTA , vonBergA , SchwabeG , SolimanS . Formoterol via Turbuhaler gave better protection than terbutaline against repeated exercise challenge for up to 12 hours in children and adolescents. Respiratory Medicine2000;94(7):661‐7. ">Gronnerod 2000 Form 4.5</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terbutaline 500 mcg</p> <p>Formoterol 9 mcg</p> <p>Formoterol 4.5 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 min, 4 h, 8 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0037" title="HancoxRJ , SubbaraoP , KamadaD , WatsonRM , HargreaveFE , InmanMD . Beta2‐agonist tolerance and exercise‐induced bronchospasm. American Journal of Respiratory and Critical Care Medicine2002;165(8):1068‐70. ">Hancox 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol 800 mcg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term (1 week)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0038" title="HawksworthRJ , SykesAP , FarisM , MantT , LeeTH . Albuterol HFA is as effective as albuterol CFC in preventing exercise‐induced bronchoconstriction. Annals of Allergy, Asthma &amp; Immunology2002;88(5):473‐7. ">Hawksworth 2002 Salb HFA</a> </p> <p><a href="./references#CD003564-bbs2-0039" title="HawksworthRJ , SykesAP , FarisM , MantT , LeeTH . Albuterol HFA is as effective as albuterol CFC in preventing exercise‐induced bronchoconstriction. Annals of Allergy, Asthma &amp; Immunology2002;88(5):473‐7. ">Hawksworth 2002 Salb MDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol 180 HFA</p> <p>Salbutamol 180 mcg MDI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 min</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0040" title="HenriksenJM , DahlR . Effects of inhaled budesonide alone and in combination with low‐dose terbutaline in children with exercise‐induced asthma. American Review of Respiratory Disease1983;128(6):993‐7. ">Henricksen 1983 Terb</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terbutaline 32.5 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 min</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0041" title="HenriksenJM , AgertoftL , PedersenS . Protective effect and duration of action of inhaled formoterol and salbutamol on exercise‐induced asthma in children. Journal of Allergy and Clinical Immunology1992;89(6):1176‐82. ">Henricksen 1992 Salb</a> </p> <p><a href="./references#CD003564-bbs2-0042" title="HenriksenJM , AgertoftL , PedersenS . Protective effect and duration of action of inhaled formoterol and salbutamol on exercise‐induced asthma in children. Journal of Allergy and Clinical Immunology1992;89(6):1176‐82. ">Henriksen 1992 Form 12</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol 200 mcg</p> <p>Formoterol 12 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 min, 3 h, 5 h 30, 8 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0043" title="HillsEA , DaviesS , GearyM . Salmefamol and salbutamol in exercise‐induced asthma in children. British Journal of Diseases of the Chest1976;70(2):78‐82. ">Hills 1976 Salb</a> </p> <p><a href="./references#CD003564-bbs2-0044" title="HillsEA , DaviesS , GearyM . Salmefamol and salbutamol in exercise‐induced asthma in children. British Journal of Diseases of the Chest1976;70(2):78‐82. ">Hills 1976 Salmefamol</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol 200 mcg</p> <p>Salmefamol 200 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 min</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0045" title="InmanMD , O'ByrnePM . The effect of regular inhaled albuterol on exercise‐induced bronchoconstriction. American Journal of Respiratory and Critical Care Medicine1996;153(1):65‐9. ">Inman 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol 800 mcg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term (81 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0046" title="KempJP , DockhornRJ , BusseWW , BleeckerER , VanAsA . Prolonged effect of inhaled salmeterol against exercise‐induced bronchospasm. American Journal of Respiratory and Critical Care Medicine 94;150:1612‐5. ">Kemp 1994 Salb</a> </p> <p><a href="./references#CD003564-bbs2-0047" title="KempJP , DockhornRJ , BusseWW , BleeckerER , VanAsA . Prolonged effect of inhaled salmeterol against exercise‐induced bronchospasm. American Journal of Respiratory and Critical Care Medicine 94;150:1612‐5. ">Kemp 1994 Salm 42</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol 180 mcg</p> <p>Salmeterol 42 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 min, 5 h 30, 11 h 30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0048" title="KonigP , EgglestonPA , SerbyCW . Comparison of oral and inhaled metaproterenol for prevention of exercise‐induced asthma. Clinical Allergy1981;11(6):597‐604. ">Konig 1981 Metaprot</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metaproterenol 130 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 min, 1 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0051" title="LarssonK . Oxitropium bromide, ipratropium bromide and fenoterol in exercise‐induced asthma. Respiration1982;43(1):57‐63. ">Larsson 1982 Fen</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fenoterol 400 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 min</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0053" title="McAlpineLG , ThomsonNC . Prophylaxis of exercise‐induced asthma with inhaled formoterol, a long‐acting beta 2‐adrenergic agonist. Respiratory Medicine1990;84(4):293‐5. ">McAlpine 1990 Salb</a> </p> <p><a href="./references#CD003564-bbs2-0052" title="McAlpineLG , ThomsonNC . Prophylaxis of exercise‐induced asthma with inhaled formoterol, a long‐acting beta 2‐adrenergic agonist. Respiratory Medicine1990;84(4):293‐5. ">McAlpine 1990 Form 12</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol 200 mcg</p> <p>Formoterol 12 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 h, 4 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0054" title="McFaddenERJr , MillsR . Prevention of exercise‐induced bronchospasm with aerosolized albuterol. Current Therapeutic Research, Clinical and Experimental1986;39(1):112‐8. ">McFadden 1986 Salb (I)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol 200 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 min</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0055" title="McFaddenER , MillsR . Inhaled albuterol powder for the prevention of exercise‐induced bronchospasm. Immunology and Allergy Practice1986;8(6):199‐203. ">McFadden 1986 Salb (II)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol 180 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 min</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0056" title="MortonAR , ScottCA , FitchKD . Rimiterol and the prevention of exercise‐induced asthma. Journal of Allergy and Clinical Immunology1989;83(1):61‐5. ">Morton 1989 Rimet</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rimeterol 400 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 min</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0057" title="NelsonJA , StraussL , SkowronskiM , CiufoR , NovakR , McFaddenERJr . Effect of long‐term salmeterol treatment on exercise‐induced asthma. New England Journal of Medicine1998;339(3):141‐6. ">Nelson 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmeterol 84 mcg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term (29 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 min, 9 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0058" title="NewnhamDM , IngramCG , EarnshawJ , PalmerJB , DhillonDP . Salmeterol provides prolonged protection against exercise‐induced bronchoconstriction in a majority of subjects with mild, stable asthma. Respiratory Medicine1993;87(6):439‐4. ">Newnham 1993 Salb 200</a> </p> <p><a href="./references#CD003564-bbs2-0059" title="NewnhamDM , IngramCG , EarnshawJ , PalmerJB , DhillonDP . Salmeterol provides prolonged protection against exercise‐induced bronchoconstriction in a majority of subjects with mild, stable asthma. Respiratory Medicine1993;87(6):439‐4. ">Newnham 1993 Salm 50</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol 200 mcg</p> <p>Salmeterol 50 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 h, 6 h, 12 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0060" title="PatelKR . Bronchodilator activity of a new inhaled beta2‐adrenoceptor agonist, tulobuterol, and its protective effect in exercise‐induced asthma. British Journal of Clinical Pharmacology1986;21(2):234‐7. ">Patel 1986 Salb 200</a> </p> <p><a href="./references#CD003564-bbs2-0061" title="PatelKR . Bronchodilator activity of a new inhaled beta2‐adrenoceptor agonist, tulobuterol, and its protective effect in exercise‐induced asthma. British Journal of Clinical Pharmacology1986;21(2):234‐7. ">Patel 1986 Tulob 200</a> </p> <p><a href="./references#CD003564-bbs2-0062" title="PatelKR . Bronchodilator activity of a new inhaled beta2‐adrenoceptor agonist, tulobuterol, and its protective effect in exercise‐induced asthma. British Journal of Clinical Pharmacology1986;21(2):234‐7. ">Patel 1986 Tulob 400</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol 200 mcg</p> <p>Tolobuterol 200 mcg</p> <p>Tolobuterol 400 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 min</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0064" title="PatessioA , PoddaA , CaroneM , TrombettaN , DonnerCF . Protective effect and duration of action of formoterol aerosol on exercise‐induced asthma. European Respiratory Journal1991;4(3):296‐300. ">Patessio 1991 Salb 200</a> </p> <p><a href="./references#CD003564-bbs2-0063" title="PatessioA , PoddaA , CaroneM , TrombettaN , DonnerCF . Protective effect and duration of action of formoterol aerosol on exercise‐induced asthma. European Respiratory Journal1991;4(3):296‐300. ">Patessio 1991 Form 24</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol 200 mcg</p> <p>Formoterol 24 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 h, 8 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0067" title="PearlmanD , MilgromH , TillD , ZiehmerB . Effect of formoterol fumarate treatment on exercise‐induced bronchoconstriction in children. Annals of Allergy, Asthma &amp; Immunology2006;97(3):382‐8. ">Pearlman 2006 Salb 180</a> </p> <p><a href="./references#CD003564-bbs2-0065" title="PearlmanD , MilgromH , TillD , ZiehmerB . Effect of formoterol fumarate treatment on exercise‐induced bronchoconstriction in children. Annals of Allergy, Asthma &amp; Immunology2006;97(3):382‐8. ">Pearlman 2006 Form 12</a> </p> <p><a href="./references#CD003564-bbs2-0066" title="PearlmanD , MilgromH , TillD , ZiehmerB . Effect of formoterol fumarate treatment on exercise‐induced bronchoconstriction in children. Annals of Allergy, Asthma &amp; Immunology2006;97(3):382‐8. ">Pearlman 2006 Form 24</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol 180 mcg</p> <p>Formoterol 12 mcg</p> <p>Formoterol 24 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 min, 4 h, 8 h, 12 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0068" title="PearlmanDS , ReesW , SchaeferK , HuangH , AndrewsWT . An evaluation of levalbuterol HFA in the prevention of exercise‐induced bronchospasm. Journal of Asthma2007;44(9):729‐33. ">Pearlman 2007 Salb 90</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol 90 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 min</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0069" title="PhilipG , PearlmanDS , VillaránC , LegrandC , LoeysT , LangdonRB , et al. Single‐dose montelukast or salmeterol as protection against exercise‐induced bronchoconstriction. Chest2007;132(3):875‐83. ">Philip 2007 Salm 50</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmeterol 50 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 h, 8 h 30, 24 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0070" title="RamageL , LipworthBJ , IngramCG , CreeIA , DhillonDP . Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respiratory Medicine1994;88(5):363‐8. ">Ramage 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmeterol 100 mcg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term (28 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 h, 12 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0073" title="RichterK , JanickiS , JorresRA , MagnussenH . Acute protection against exercise‐induced bronchoconstriction by formoterol, salmeterol and terbutaline. European Respiratory Journal2002;19(5):865‐71. ">Richter 2002 Terb 500</a> </p> <p><a href="./references#CD003564-bbs2-0071" title="RichterK , JanickiS , JorresRA , MagnussenH . Acute protection against exercise‐induced bronchoconstriction by formoterol, salmeterol and terbutaline. European Respiratory Journal2002;19(5):865‐71. ">Richter 2002 Form 12</a> </p> <p><a href="./references#CD003564-bbs2-0072" title="RichterK , JanickiS , JorresRA , MagnussenH . Acute protection against exercise‐induced bronchoconstriction by formoterol, salmeterol and terbutaline. European Respiratory Journal2002;19(5):865‐71. ">Richter 2002 Salm 50</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terbutaline 500 mcg</p> <p>Formoterol 12 mcg</p> <p>Salmeterol 50 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 min, 30 min, 1 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0212" title="ShapiroGS , YegenU , XiangJ , KottakisJ , Della CioppaG . A randomized, double‐blind, single‐dose, crossover clinical trial of the onset and duration of protection from exercise‐induced bronchoconstriction by formoterol and albuterol. Clinical Therapeutics2002;24(12):2077‐87. ">Shapiro 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol 180 mcg</p> <p>Formoterol 12 mcg</p> <p>Formoterol 24 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 min, 4 h, 8 h, 12 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0077" title="SimonsFE , GerstnerTV , CheangMS . Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise‐induced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics1997;99(5):655‐9. ">Simons 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmeterol 50 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term (28 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 h, 9 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0078" title="StelmachI , GrzelewskiT , MajakP , JerzynskaJ , StelmachW , KunaP . Effect of different antiasthmatic treatments on exercise‐induced bronchoconstriction in children with asthma. Journal of Allergy and Clinical Immunology2008;121(2):383‐9. ">Stelmach 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Formoterol 9 mcg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term (28 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 h, 9 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0079" title="StormsW , ChervinskyP , GhannamAF , BirdS , HustadCM , EdelmanJM , et al. A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge. Respiratory Medicine2004;98(11):1051‐62. ">Storms 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmeterol 100 mcg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term (28 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 h, 9 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0080" title="SturaniC , SchiavinaM , TosiI , GunellaG . Comparison of inhaled fenoterol and salbutamol in the prevention of exercise‐induced asthma. European Journal of Respiratory Diseases1983;128(Suppl):526‐8. ">Sturani 1983 Fen 400</a> </p> <p><a href="./references#CD003564-bbs2-0081" title="SturaniC , SchiavinaM , TosiI , GunellaG . Comparison of inhaled fenoterol and salbutamol in the prevention of exercise‐induced asthma. European Journal of Respiratory Diseases1983;128:526‐8. ">Sturani 1983 Salb 200</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fenoterol 400 mcg</p> <p>Salbutamol 200 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 min</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0082" title="VanHaitsma TA ,  MickleboroughT , StagerJM , KocejaDM ,  LindleyMR , ChapmanR . Comparative effects of caffeine and albuterol on the bronchoconstrictor response to exercise in asthmatic athletes. International Journal of Sports Medicine2010;31(4):231‐6. ">VanHaitsma 2010 Salb</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol 180 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 min</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0083" title="VazquezC , FidalgoI , VirtoMC , LabayruMT , CasasC . Efficacy of disodium chromoglycate, salbutamol and ipratroprium bromide on inhibition of exercise induced bronchospasm. Anales Espanoles de Pediatria1984;20(8):756‐62. ">Vasquez 1984 Salb 400</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol 400 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 min</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0084" title="WalkerSB , BiermanCW , PiersonWE , ShapiroGG , FurukawaCT , MingoTS . Bitolterol mesylate in exercise‐induced asthma. Journal of Allergy and Clinical Immunology1986;77:32‐6. ">Walker 1986 Bitolterol</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bitolterol 1050 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 min</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0085" title="WoolleyM , AndersonSD , QuigleyBM . Duration of protective effect of terbutaline sulfate and cromolyn sodium alone and in combination on exercise‐induced asthma. Chest1990;97(1):39‐45. ">Wolley 1990 Terb 500</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terbutaline 500 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 min, 2 h, 4 h, 6 h</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD003564-sec-0047"> <h5 class="title">Outcomes</h5> <p>As per inclusion criteria, all 53 included studies reported data on at least one primary outcome of this review. </p> </section> </section> <section id="CD003564-sec-0048"> <h4 class="title">Excluded studies</h4> <p>See <a href="./references#CD003564-sec-0089" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD003564-sec-0049"> <h3 class="title">Risk of bias in included studies</h3> <p>An assessment of the risk of bias is presented in the <a href="./references#CD003564-sec-0088" title="">Characteristics of included studies</a> tables and is summarised in a risk of bias figure (<a href="#CD003564-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD003564-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003564-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_n/nCD003564-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD003564-sec-0050"> <h4 class="title">Allocation</h4> <p>Most of the included studies were judged at unclear risk for selection bias. Lack of information provided on random sequence generation and on allocation concealment may be explained by the high number of papers (40/53) conducted before 2000, when reporting of these risk of bias criteria was less common. </p> </section> <section id="CD003564-sec-0051"> <h4 class="title">Blinding</h4> <p>Risks of performance and detection bias were minimised by the narrow inclusion criteria adopted, which allow inclusion in the systematic review of only randomised, at least double‐blind, placebo‐controlled trials. </p> </section> <section id="CD003564-sec-0052"> <h4 class="title">Incomplete outcome data</h4> <p>Three drug arms ( <a href="./references#CD003564-bbs2-0049" title="KonigP , HordvikNL , SerbyCW . Fenoterol in exercise‐induced asthma: effect of dose on efficacy and duration of action. Chest1984;85:462‐4. ">Konig 1984 Fen 0.4</a>; <a href="./references#CD003564-bbs2-0050" title="KonigP , HordvikNL , SerbyCW . Fenoterol in exercise‐induced asthma: effect of dose on efficacy and duration of action. Chest1984;85:462‐4. ">Konig 1984 Fen 0.8</a>; <a href="./references#CD003564-bbs2-0008" title="BouletLP , TurcotteH , TenninaS . Comparative efficacy of salbutamol, ipratropium, and cromoglycate in the prevention of bronchospasm induced by exercise and hyperosmolar challenges. Journal of Allergy and Clinical Immunology1989;83(5):882‐7. ">Boulet 1989 Salb</a>) reported incomplete data on outcomes as specified in this systematic review and were therefore assigned a high risk of bias. </p> </section> <section id="CD003564-sec-0053"> <h4 class="title">Selective reporting</h4> <p>All studies except one (<a href="./references#CD003564-bbs2-0031" title="FerrariM , BalestreriF , BaratieriS , BiasinC , OldaniV , Lo CascioV . Evidence of the rapid protective effect of formoterol dry‐powder inhalation against exercise‐induced bronchospasm in athletes with asthma. Respiration2000;67(5):510‐3. ">Ferrari 2000 Form 12</a>) were rated as having unclear risk for reporting bias. </p> </section> <section id="CD003564-sec-0054"> <h4 class="title">Other potential sources of bias</h4> <p>The possibility of publication bias was investigated in the funnel plot shown in <a href="#CD003564-fig-0003">Figure 3</a>. The presence of other potential sources of bias was rated as unclear risk because of the scarce information provided. </p> <div class="figure" id="CD003564-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Beta2‐agonists versus placebo (single administration), outcome: 1.1 Maximal percentage fall in FEV1." data-id="CD003564-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_n/nCD003564-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Beta<sub>2</sub>‐agonists versus placebo (single administration), outcome: 1.1 Maximal percentage fall in FEV<sub>1</sub>. </p> </div> </div> </div> <p>Several papers reported data derived from industry‐funded studies.</p> </section> </section> <section id="CD003564-sec-0055"> <h3 class="title" id="CD003564-sec-0055">Effects of interventions</h3> <p>See: <a href="./full#CD003564-tbl-0001"><b>Summary of findings for the main comparison</b> Beta<sub>2</sub>‐agonists compared with placebo (single administration) for exercise‐induced asthma</a> </p> <p>Effects of intervention were separately assessed for short‐term (single administration) and long‐term beta<sub>2</sub>‐agonist administration. </p> <section id="CD003564-sec-0056"> <h4 class="title">Short‐term administration</h4> <p>The 45 studies evaluating short‐term beta<sub>2</sub>‐agonist administration included 77 arms of active treatment (49 SABA and 28 LABA) in comparison with placebo. </p> <section id="CD003564-sec-0057"> <h5 class="title">Primary outcomes</h5> <p>Data on max % fall in FEV<sub>1</sub> were provided by 77 arms. Effects of SABA short‐term administration were evaluated beyond the pharmacological half‐life (1 hour) in five studies, which were therefore excluded. Analysis of the remaining 72 arms, including 799 participants (<a href="#CD003564-fig-0004">Figure 4</a>), showed a significant protective effect of beta<sub>2</sub>‐agonists compared with placebo (MD ‐17.67%, 95% CI ‐19.51% to ‐15.84%; P = 0.00001). In particular, 58 study arms favoured the active treatment, and 14 trial arms reported no significant difference. Heterogeneity was, however, high (I<sup>2</sup> = 71%). </p> <div class="figure" id="CD003564-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 beta2‐agonists versus placebo (single administration), outcome: 1.1 Maximal percentage fall in FEV1." data-id="CD003564-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_n/nCD003564-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 beta<sub>2</sub>‐agonists versus placebo (single administration), outcome: 1.1 Maximal percentage fall in FEV1. </p> </div> </div> </div> <p>Mean % protection was 66% (range 29% to 91%). In seven studies, beta<sub>2</sub>‐agonist administration not only completely protected participants from EIA but also induced a bronchodilator effect compared with baseline values. In only one case (<a href="./references#CD003564-bbs2-0010" title="BronskyEA , SpectorSL , PearlmanDS , JustusSE , BishopAL . Albuterol aerosol versus albuterol Rotacaps in exercise‐induced bronchospasm in children. Journal of Asthma1995;32(3):207‐14. ">Bronski 1995 Salb Pwd</a>), placebo offered greater protection compared with the active treatment. </p> <p>Seventeen studies evaluating LABA short‐term administration at different time points showed an FEV<sub>1</sub> % fall AUC that favoured the active treatment. Different study designs prevented merging of the data in a unique comprehensive analysis. </p> </section> <section id="CD003564-sec-0058"> <h5 class="title">Secondary outcomes</h5> <p>Secondary outcomes on pulmonary function parameters confirmed a positive protective effect of beta<sub>2</sub>‐agonists on EIA compared with placebo. Complete protection from EIA as assessed by numbers of participants with an FEV<sub>1</sub> % fall &lt; 10% was evaluated in 19 studies (<a href="./references#CD003564-fig-0010" title="">Analysis 1.2</a>). A significant difference was noted in the number of participants completely protected (OR 0.08, 95% CI 0.06 to 0.13; P = 0.00001). Similar results were obtained for thresholds of FEV<sub>1</sub> fall set at 15% (OR 0.06, 95% CI 0.03 to 0.15) and 20% (OR 0.09, 95% CI 0.06 to 0.14) (<a href="./references#CD003564-fig-0011" title="">Analysis 1.3</a>; <a href="./references#CD003564-fig-0012" title="">Analysis 1.4</a>). Max PEF and FEF25‐75 % fall were assessed, respectively, in 14 and in 8 studies (<a href="./references#CD003564-fig-0013" title="">Analysis 1.5</a>; <a href="./references#CD003564-fig-0014" title="">Analysis 1.6</a>). However, statistical analysis for these two outcomes was based on a limited number of trials because dispersion data were lacking in most of the studies considered. Only three arms (<a href="./references#CD003564-bbs2-0083" title="VazquezC , FidalgoI , VirtoMC , LabayruMT , CasasC . Efficacy of disodium chromoglycate, salbutamol and ipratroprium bromide on inhibition of exercise induced bronchospasm. Anales Espanoles de Pediatria1984;20(8):756‐62. ">Vasquez 1984 Salb 400</a>; <a href="./references#CD003564-bbs2-0016" title="CarlsenKH , RoksundO , OlsholtK , NjåF , LeegaardJ , BrattenG . Overnight protection by inhaled salmeterol on exercise‐induced asthma in children. European Respiratory Journal1995;8(11):1852‐5. ">Carlsen 1995 Salm 25</a>; <a href="./references#CD003564-bbs2-0017" title="CarlsenKH , RoksundO , OlsholtK , NjåF , LeegaardJ , BrattenG . Overnight protection by inhaled salmeterol on exercise‐induced asthma in children. European Respiratory Journal1995;8(11):1852‐5. ">Carlsen 1995 Salm 50</a>) reported data on max MEF25‐50 % fall. No study provided information on changes in symptoms and sign scores and effects on physical performance. </p> <p>As far as they concern secondary outcomes related to safety, side effects were assessed in 55 trials (<a href="#CD003564-fig-0005">Figure 5</a>). Among these, 42 arms reported no adverse event for either active or placebo treatment. Analysis of the remaining 13 trials showed no significant difference between beta<sub>2</sub>‐agonists and placebo. </p> <div class="figure" id="CD003564-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Beta2‐agonists versus placebo (single administration), outcome: 1.1 Side effects." data-id="CD003564-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_n/nCD003564-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Beta<sub>2</sub>‐agonists versus placebo (single administration), outcome: 1.1 Side effects. </p> </div> </div> </div> </section> <section id="CD003564-sec-0059"> <h5 class="title">Subgroup analysis</h5> <p>The high heterogeneity (I<sup>2</sup> = 71%) found for the primary outcome max FEV<sub>1</sub> % fall was investigated through the preplanned subgroup analysis. </p> <p>We performed a subgroup analysis according to types of beta<sub>2</sub>‐agonists (SABA vs LABA; <a href="#CD003564-fig-0006">Figure 6</a>). Although subgroup analysis confirmed a significant bronchoprotective effect against EIA for both classes compared with placebo, it was not able to explain the marked heterogeneity observed in the entire population sample: SABA (I<sup>2</sup> = 71%) and LABA (I<sup>2</sup> = 67%). Accordingly, non‐significant differences emerged from the analysis of the different beta<sub>2</sub>‐agonist molecules administered (<a href="#CD003564-fig-0007">Figure 7</a>). This evaluation was plotted only for the comparison between formoterol and salmeterol, because the number of studies evaluating different SABA molecules, apart from salbutamol, appeared to be too small for a reliable investigation. It is interesting to note that analysis of studies performed only in adults (n = 19) compared with those performed only in children (n = 32) showed that high heterogeneity was largely confined to studies in children (I<sup>2</sup> = 11% and 80%, respectively), despite the comparable mean bronchoprotective effect (<a href="#CD003564-fig-0008">Figure 8</a>). Furthermore all studies that failed to show a positive protective effect against EIA of beta<sub>2</sub>‐agonists compared with placebo dealt with the paediatric population. </p> <div class="figure" id="CD003564-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Beta2‐agonists versus placebo (single administration), outcome: 1.8 Subgroup analysis: maximal percentage fall in FEV1 SABA versus LABA." data-id="CD003564-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_n/nCD003564-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Beta<sub>2</sub>‐agonists versus placebo (single administration), outcome: 1.8 Subgroup analysis: maximal percentage fall in FEV<sub>1</sub> SABA versus LABA. </p> </div> </div> </div> <div class="figure" id="CD003564-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Beta2‐agonists versus placebo (single administration), outcome: 1.9 Subgroup analysis: maximal percentage fall in FEV1: salmeterol versus formoterol." data-id="CD003564-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_n/nCD003564-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Beta<sub>2</sub>‐agonists versus placebo (single administration), outcome: 1.9 Subgroup analysis: maximal percentage fall in FEV<sub>1</sub>: salmeterol versus formoterol. </p> </div> </div> </div> <div class="figure" id="CD003564-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Beta2‐agonists versus placebo (single administration), outcome: 1.10 Subgroup analysis: maximal percentage fall in FEV1: adults versus children." data-id="CD003564-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_n/nCD003564-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Beta<sub>2</sub>‐agonists versus placebo (single administration), outcome: 1.10 Subgroup analysis: maximal percentage fall in FEV<sub>1</sub>: adults versus children. </p> </div> </div> </div> <p>The different study designs used and the limited information provided prevented assessment of the potential role of concomitant treatment with inhaled corticosteroids. </p> </section> </section> <section id="CD003564-sec-0060"> <h4 class="title">Long‐term administration</h4> <p>Long‐term beta<sub>2</sub>‐agonist administration was addressed in only eight papers. Five trials were performed with a cross‐over design in a total of 64 people (50 adults and 14 children). Three studies adopted a parallel‐group design and included 69 people (49 adults and 20 children) in the active arms and 73 (53 adults and 20 children) placebo controls. Treatment periods range from 7 to 29 days. Effects of SABA were evaluated in two protocols, and LABA administration was assessed in six studies. The limited number of trials, the small population samples and the different study designs and drugs tested allow only a descriptive approach and prevent plotting of data in a meta‐analysis. </p> <p>Garcia and coauthors (<a href="./references#CD003564-bbs2-0032" title="GarciaR , GuerraP , FeoF , GalindoPA , GómezE , BorjaJ , et al. Tachyphylaxis following regular use of formoterol in exercise‐induced bronchospasm. Journal of Investigational Allergology and Clinical Immunology2001;11(3):176‐82. ">Garcia 2001 Form 12</a>) evaluated the effects of 28‐day formoterol administration in a parallel‐group design (10 people in the beta<sub>2</sub>‐agonist arm and 9 people in the placebo arm). The protective effect of salmeterol 12 mcg twice daily was assessed on the 1st, 14th and 28th study days, and results were not significantly greater than those provided by placebo at any time point. Furthermore, tachyphylaxis to the beta<sub>2</sub>‐agonist effect was developed already after two weeks of treatment, although it was not progressive. </p> <p>Hancox (<a href="./references#CD003564-bbs2-0037" title="HancoxRJ , SubbaraoP , KamadaD , WatsonRM , HargreaveFE , InmanMD . Beta2‐agonist tolerance and exercise‐induced bronchospasm. American Journal of Respiratory and Critical Care Medicine2002;165(8):1068‐70. ">Hancox 2002</a>) studied the effect of 200 mcg once daily of salbutamol in eight adults treated for seven days in a cross‐over study. Results showed not only an increased max FEV<sub>1</sub> % fall after the exercise challenge, but also a sub‐optimal bronchodilator response to further beta<sub>2</sub>‐agonist administration at the end of the treatment period in the active group. </p> <p>Ten adults who inhaled 200 mcg of salbutamol or placebo four times a day for seven days were studied by Inman and O'Byrne (<a href="./references#CD003564-bbs2-0045" title="InmanMD , O'ByrnePM . The effect of regular inhaled albuterol on exercise‐induced bronchoconstriction. American Journal of Respiratory and Critical Care Medicine1996;153(1):65‐9. ">Inman 1996</a>) in a cross‐over study. One week of regular inhaled salbutamol resulted in worsening of EIA. </p> <p>A cross‐over design was also adopted by Nelson (<a href="./references#CD003564-bbs2-0057" title="NelsonJA , StraussL , SkowronskiM , CiufoR , NovakR , McFaddenERJr . Effect of long‐term salmeterol treatment on exercise‐induced asthma. New England Journal of Medicine1998;339(3):141‐6. ">Nelson 1998</a>) in 20 adults treated for a month with inhaled salmeterol 42 mcg twice a day. Significant beta<sub>2</sub>‐agonist protection against EIA was maintained for the entire study period. However, the length of time that the drug remained active after a single dose significantly decreased. Furthermore, the number of participants for whom salmeterol did not offer complete protection against EIA (FEV<sub>1</sub> % fall &lt; 10%) increased from two on study day 1 to 11 on day 29 (P = 0.02) </p> <p>Ramage and coworkers (<a href="./references#CD003564-bbs2-0070" title="RamageL , LipworthBJ , IngramCG , CreeIA , DhillonDP . Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respiratory Medicine1994;88(5):363‐8. ">Ramage 1994</a>) studied 12 adults treated with inhaled salmeterol 50 mcg twice daily for 4 weeks in a cross‐over manner. The significant protection provided by the first dose of salmeterol against EIA at 6 and 12 hours was no longer present at the end of the treatment period. </p> <p>Fourteen children were studied by Simons (<a href="./references#CD003564-bbs2-0077" title="SimonsFE , GerstnerTV , CheangMS . Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise‐induced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics1997;99(5):655‐9. ">Simons 1997</a>) in a four‐week cross‐over study. The first dose of salmeterol had an excellent bronchoprotective effect against EIA at 1 and 9 hours. At the end of the study, however, the bronchoprotective effect was significantly greater than that of placebo only at 1 hour. </p> <p>A parallel‐group study design was adopted by Stelmach (<a href="./references#CD003564-bbs2-0078" title="StelmachI , GrzelewskiT , MajakP , JerzynskaJ , StelmachW , KunaP . Effect of different antiasthmatic treatments on exercise‐induced bronchoconstriction in children with asthma. Journal of Allergy and Clinical Immunology2008;121(2):383‐9. ">Stelmach 2008</a>) to compare the effects of formoterol 9 mcg daily against placebo in two arms, each consisting of 20 children. Both groups of people were receiving concomitant inhaled corticosteroid (ICS) treatment with budesonide 100 mcg daily. At the end of the four‐week treatment period, bronchoconstriction induced by a standardised treadmill exercise challenge was significantly diminished in the active group compared with the placebo group, </p> <p>At last, Storms (<a href="./references#CD003564-bbs2-0079" title="StormsW , ChervinskyP , GhannamAF , BirdS , HustadCM , EdelmanJM , et al. A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge. Respiratory Medicine2004;98(11):1051‐62. ">Storms 2004</a>) in a four‐week parallel‐group study compared the protective effect of salmeterol 50 mcg twice daily against placebo. All enrolled people were receiving concomitant 100 mcg twice‐daily fluticasone treatment. The protective effect against EIA was evaluated at weeks 1 and 4 and was not different between the two groups. </p> <p>Only one study (<a href="./references#CD003564-bbs2-0077" title="SimonsFE , GerstnerTV , CheangMS . Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise‐induced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics1997;99(5):655‐9. ">Simons 1997</a>) took into consideration safety aspects of long‐term beta<sub>2</sub>‐adrenergic administration. Reported side effects were minor, were poorly related to study drug and anyway were not different between active and placebo groups. </p> <p>The overall evaluation of presented studies seems to confirm the beta<sub>2</sub>‐agonist bronchoprotective effect for the first dose of treatment. However, long‐term use of both SABA and LABA induced the development of tolerance and decreased the duration of drug effect, even after short‐term treatment. The few available data on concomitant therapy with inhaled corticosteroids did not allow a firm statement about their potential influence on the response to beta<sub>2</sub>‐agonists. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003564-sec-0061" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003564-sec-0061"></div> <section id="CD003564-sec-0062"> <h3 class="title" id="CD003564-sec-0062">Summary of main results</h3> <p>Evidence emerging from the meta‐analysis of 45 short‐term (single administration) studies shows that both short‐ and long‐acting beta<sub>2</sub>‐agonists administered as preventive treatment (within the time‐effect period set at one hour for SABA and at 12 hours for LABA) prevent exercise‐induced asthma, as shown by the primary outcomes related to the FEV<sub>1</sub> fall. This pharmacological effect appears to be clinically relevant and independent of the exercise challenge adopted (treadmill, cycle ergometer, free run). The assessment of secondary outcomes considered shows that the beta<sub>2</sub>‐agonist preventive effect is also documented by the number of participants protected (complete protection detectable in 68% of participants) and by other pulmonary function variables (PEF, FEF 25%‐75%, MEF 50%) and beta<sub>2</sub>‐agonists did not cause side effects. </p> </section> <section id="CD003564-sec-0063"> <h3 class="title" id="CD003564-sec-0063">Overall completeness and applicability of evidence</h3> <p>The choice to include only double‐blind randomised trials may influence the completeness of the present review but was thought to reinforce the quality of evidence. </p> </section> <section id="CD003564-sec-0064"> <h3 class="title" id="CD003564-sec-0064">Quality of the evidence</h3> <p>The quality of the evidence gathered for the primary outcome of maximal percentage fall in FEV<sub>1</sub> and the number of participants with a fall in FEV<sub>1</sub> greater than 10% were moderate owing to some concerns about risk of bias (unclear allocation concealment) and detected and not completely explained inconsistency and indirectness (relation of FEV<sub>1</sub> to patient‐important outcomes). The same concerns apply to all other outcomes reported in the 'Summary of findings' (SoF) Table. In addition, for the outcomes of maximal percentage fall in PEF, maximal percentage fall in FEF 25‐75 and side effects, the quality was lowered further by the small numbers of participants for these outcomes and the resulting wide confidence intervals. It can be argued that this review started with the premise that pulmonary function measures are patient‐important outcomes and that, therefore, the quality of evidence should not be lowered for indirectness because the primary outcome was measured in these studies. However, despite these considerations, the meaning of the degree of change in FEV<sub>1</sub> for patients remains unclear (as well as how it relates to their well‐being). Furthermore, (small) concerns about inconsistency and risk of bias justify an overall rating of quality as presented in the SoF Table. Further research should focus on patient‐important outcomes and the imprecision that was encountered for many of the secondary outcomes. </p> </section> <section id="CD003564-sec-0065"> <h3 class="title" id="CD003564-sec-0065">Potential biases in the review process</h3> <p>The review process was protected from bias by adherence to a prepublished protocol. We tried to prevent bias in our search process by using comprehensive search terms and by asking study authors to identify other published and non‐published studies. We minimised bias by assessing studies independently and resolving differences of opinion by discussion. Extraction of data and assessment of risk of bias were performed in duplicate as well. We performed only subgroup analyses that were specified a priori in the protocol. </p> </section> <section id="CD003564-sec-0066"> <h3 class="title" id="CD003564-sec-0066">Agreements and disagreements with other studies or reviews</h3> <p>Our results appear to be in agreement with those obtained by Spooner and coworkers in a Cochrane review and meta‐analysis published in 2009 and focused on quantitative comparison of the effects of inhaling mast cell stabilisers (nedocromil sodium or sodium cromoglycate) versus beta<sub>2</sub>‐agonists (<a href="./references#CD003564-bbs2-0213" title="Spooner CH ,  Spooner GR ,  RoweBH . Mast‐cell stabilising agents to prevent exercise‐induced bronchoconstriction. Cochrane Database of Systematic Reviews2003, Issue 4. [DOI: 10.1002/14651858.CD002307] ">Spooner 2003</a>). However, the review authors confined their review to single‐dose administration and to short‐acting beta<sub>2</sub>‐agonist molecules. As far as we know, no recent systematic reviews have specifically addressed the efficacy and safety of both SABA and LABA, in short‐term and long‐term administration, for prevention of exercise‐induced asthma. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003564-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/urn:x-wiley:14651858:media:CD003564:CD003564-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_t/tCD003564-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD003564-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_n/nCD003564-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/full#CD003564-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_n/nCD003564-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003564-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/urn:x-wiley:14651858:media:CD003564:CD003564-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_t/tCD003564-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003564-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_n/nCD003564-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/full#CD003564-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_n/nCD003564-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003564-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/urn:x-wiley:14651858:media:CD003564:CD003564-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_t/tCD003564-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Beta2‐agonists versus placebo (single administration), outcome: 1.1 Maximal percentage fall in FEV1." data-id="CD003564-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_n/nCD003564-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Beta<sub>2</sub>‐agonists versus placebo (single administration), outcome: 1.1 Maximal percentage fall in FEV<sub>1</sub>. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/full#CD003564-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_n/nCD003564-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003564-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/urn:x-wiley:14651858:media:CD003564:CD003564-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_t/tCD003564-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 beta2‐agonists versus placebo (single administration), outcome: 1.1 Maximal percentage fall in FEV1." data-id="CD003564-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_n/nCD003564-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 beta<sub>2</sub>‐agonists versus placebo (single administration), outcome: 1.1 Maximal percentage fall in FEV1. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/full#CD003564-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_n/nCD003564-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003564-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/urn:x-wiley:14651858:media:CD003564:CD003564-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_t/tCD003564-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Beta2‐agonists versus placebo (single administration), outcome: 1.1 Side effects." data-id="CD003564-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_n/nCD003564-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Beta<sub>2</sub>‐agonists versus placebo (single administration), outcome: 1.1 Side effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/full#CD003564-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_n/nCD003564-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003564-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/urn:x-wiley:14651858:media:CD003564:CD003564-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_t/tCD003564-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Beta2‐agonists versus placebo (single administration), outcome: 1.8 Subgroup analysis: maximal percentage fall in FEV1 SABA versus LABA." data-id="CD003564-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_n/nCD003564-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Beta<sub>2</sub>‐agonists versus placebo (single administration), outcome: 1.8 Subgroup analysis: maximal percentage fall in FEV<sub>1</sub> SABA versus LABA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/full#CD003564-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_n/nCD003564-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003564-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/urn:x-wiley:14651858:media:CD003564:CD003564-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_t/tCD003564-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Beta2‐agonists versus placebo (single administration), outcome: 1.9 Subgroup analysis: maximal percentage fall in FEV1: salmeterol versus formoterol." data-id="CD003564-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_n/nCD003564-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Beta<sub>2</sub>‐agonists versus placebo (single administration), outcome: 1.9 Subgroup analysis: maximal percentage fall in FEV<sub>1</sub>: salmeterol versus formoterol. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/full#CD003564-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_n/nCD003564-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003564-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/urn:x-wiley:14651858:media:CD003564:CD003564-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_t/tCD003564-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Beta2‐agonists versus placebo (single administration), outcome: 1.10 Subgroup analysis: maximal percentage fall in FEV1: adults versus children." data-id="CD003564-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_n/nCD003564-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Beta<sub>2</sub>‐agonists versus placebo (single administration), outcome: 1.10 Subgroup analysis: maximal percentage fall in FEV<sub>1</sub>: adults versus children. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/full#CD003564-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_n/nCD003564-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003564-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/urn:x-wiley:14651858:media:CD003564:CD003564-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_t/tCD003564-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Beta2‐agonists versus placebo (single administration), Outcome 1 Maximal percentage fall in FEV1." data-id="CD003564-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_n/nCD003564-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Beta<sub>2</sub>‐agonists versus placebo (single administration), Outcome 1 Maximal percentage fall in FEV<sub>1</sub>. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/references#CD003564-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_n/nCD003564-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003564-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/urn:x-wiley:14651858:media:CD003564:CD003564-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_t/tCD003564-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Beta2‐agonists versus placebo (single administration), Outcome 2 Number of participants with an FEV1 fall &gt; 10%." data-id="CD003564-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_n/nCD003564-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Beta<sub>2</sub>‐agonists versus placebo (single administration), Outcome 2 Number of participants with an FEV<sub>1</sub> fall &gt; 10%. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/references#CD003564-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_n/nCD003564-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003564-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/urn:x-wiley:14651858:media:CD003564:CD003564-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_t/tCD003564-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Beta2‐agonists versus placebo (single administration), Outcome 3 Number of participants with an FEV1 fall &gt; 15%." data-id="CD003564-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_n/nCD003564-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Beta<sub>2</sub>‐agonists versus placebo (single administration), Outcome 3 Number of participants with an FEV<sub>1</sub> fall &gt; 15%. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/references#CD003564-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_n/nCD003564-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003564-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/urn:x-wiley:14651858:media:CD003564:CD003564-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_t/tCD003564-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Beta2‐agonists versus placebo (single administration), Outcome 4 Number of participants with an FEV1 fall &gt; 20%." data-id="CD003564-fig-0012" src="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_n/nCD003564-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Beta<sub>2</sub>‐agonists versus placebo (single administration), Outcome 4 Number of participants with an FEV<sub>1</sub> fall &gt; 20%. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/references#CD003564-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_n/nCD003564-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003564-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/urn:x-wiley:14651858:media:CD003564:CD003564-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_t/tCD003564-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Beta2‐agonists versus placebo (single administration), Outcome 5 Maximal percentage fall in PEF." data-id="CD003564-fig-0013" src="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_n/nCD003564-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Beta<sub>2</sub>‐agonists versus placebo (single administration), Outcome 5 Maximal percentage fall in PEF. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/references#CD003564-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_n/nCD003564-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003564-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/urn:x-wiley:14651858:media:CD003564:CD003564-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_t/tCD003564-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Beta2‐agonists versus placebo (single administration), Outcome 6 Maximal percentage fall in FEF 25‐75." data-id="CD003564-fig-0014" src="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_n/nCD003564-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Beta<sub>2</sub>‐agonists versus placebo (single administration), Outcome 6 Maximal percentage fall in FEF 25‐75. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/references#CD003564-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_n/nCD003564-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003564-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/urn:x-wiley:14651858:media:CD003564:CD003564-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_t/tCD003564-CMP-001-07.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Beta2‐agonists versus placebo (single administration), Outcome 7 Side effects." data-id="CD003564-fig-0015" src="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_n/nCD003564-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Beta<sub>2</sub>‐agonists versus placebo (single administration), Outcome 7 Side effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/references#CD003564-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_n/nCD003564-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003564-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/urn:x-wiley:14651858:media:CD003564:CD003564-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_t/tCD003564-CMP-001-08.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Beta2‐agonists versus placebo (single administration), Outcome 8 Subgroup analysis: maximal percentage fall in FEV1 SABA vs LABA." data-id="CD003564-fig-0016" src="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_n/nCD003564-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Beta<sub>2</sub>‐agonists versus placebo (single administration), Outcome 8 Subgroup analysis: maximal percentage fall in FEV<sub>1</sub> SABA vs LABA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/references#CD003564-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_n/nCD003564-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003564-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/urn:x-wiley:14651858:media:CD003564:CD003564-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_t/tCD003564-CMP-001-09.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Beta2‐agonists versus placebo (single administration), Outcome 9 Subgroup analysis: maximal percentage fall in FEV1: salmeterol versus formoterol." data-id="CD003564-fig-0017" src="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_n/nCD003564-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Beta<sub>2</sub>‐agonists versus placebo (single administration), Outcome 9 Subgroup analysis: maximal percentage fall in FEV<sub>1</sub>: salmeterol versus formoterol. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/references#CD003564-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_n/nCD003564-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003564-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/urn:x-wiley:14651858:media:CD003564:CD003564-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_t/tCD003564-CMP-001-10.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Beta2‐agonists versus placebo (single administration), Outcome 10 Subgroup analysis: maximal percentage fall in FEV1: adults versus children." data-id="CD003564-fig-0018" src="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_n/nCD003564-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Beta<sub>2</sub>‐agonists versus placebo (single administration), Outcome 10 Subgroup analysis: maximal percentage fall in FEV<sub>1</sub>: adults versus children. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/references#CD003564-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/media/CDSR/CD003564/image_n/nCD003564-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD003564-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Beta2‐agonists compared with placebo (single administration) for exercise‐induced asthma</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Beta<sub>2</sub>‐agonists compared with placebo (single administration) for exercise‐induced asthma</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> exercise‐induced asthma <br/> <b>Intervention:</b> beta<sub>2</sub>‐agonists<br/> <b>Comparison:</b> placebo (single administration) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo (single administration)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Beta<sub>2</sub>‐agonists</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maximal percentage fall in FEV<sub>1</sub> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean fall in FEV<sub>1</sub> in the intervention group was MD 17.67 lower (19.51 lower to 15.84 lower)<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>－</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>799<br/> (72 studies)<sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>d,e,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The results in the subgroup of LABA and SABA were similar: MD 15.6 lower (18.29 lower to 12.92 lower) and MD 18.99 lower (21.38 lower to 16.6 lower) in 44 and 28 studies, respectively </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with an FEV<sub>1</sub> fall &gt; 10% </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>843 per 1000 (84.3)%</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 per 1000<br/> (243 to 410) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.08</b> (0.06 to 0.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>773<br/> (19 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>d,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maximal percentage fall in PEF</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean maximal percentage fall in PEF in the intervention group was MD 24.61 lower (37.57 lower to 11.65 lower)<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>－</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92<br/> (14 studies)<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>d,e,g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Maximal percentage fall in FEF<sub>25‐75%</sub> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean maximal percentage fall in FEF<sub>25‐75%</sub> in the intervention group was MD 20.75 lower (27.17 lower to 14.32 lower)<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>－</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106<br/> (8 studies)<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>d,e,g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Side effects</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000 (5.0)%</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>42 per 1000<br/> (22 to 77) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.83</b> (0.43 to 1.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2165<br/> (55 studies)<sup>h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>e,g,I</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; FEF<sub>25‐75%</sub>: forced expiratory flow 25–75%; FEV1: forced expiratory volume in 1 minute; LABA: long‐acting beta<sub>2</sub>‐agonist; MD: mean difference; OR: odds ratio; peak expiratory flow (PEF); SABA: short‐acting beta<sub>2</sub>‐agonist. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Lower indicates that beta<sub>2</sub>‐agonists are better than placebo. </p> <p><sup>b</sup>In 51 studies that provided data for subgroup analysis, no difference was observed in the maximal percentage fall in FEV<sub>1</sub>, but the heterogeneity of the effect was seen primarily in the paediatric population. </p> <p><sup>c</sup>These represent 72 study arms from 53 studies. </p> <p><sup>d</sup>It is unclear how directly pulmonary function measures relate to what participants feel. </p> <p><sup>e</sup>There was concern about lack of concealment, loss to follow‐up and reporting bias. </p> <p><sup>f</sup>Inconsistency was moderate to high and was explained in part by subgroup analyses of adults and children. </p> <p><sup>g</sup>Small numbers of participants were included with resulting wide confidence intervals. </p> <p><sup>h</sup>These represent 55 study arms rather than studies. </p> <p><sup>i</sup>This represents a mix of outcomes, and not all of them are of equal importance to patients. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Beta2‐agonists compared with placebo (single administration) for exercise‐induced asthma</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/full#CD003564-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003564-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of study interventions</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intervention (single dose)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study type (single‐dose test or chronic [duration])</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>When administered before challenge/exercise (min, h)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0001" title="AndersonSD , LambertS , BrannanJD , WoodRJ , KoskelaH , MortonAR , et al. Laboratory protocol for exercise asthma to evaluate salbutamol given by two devices. Medicine &amp; Science in Sports &amp; Exercise2001;33(6):893‐900. ">Anderson 2001 Salb Disk</a>; </p> <p><a href="./references#CD003564-bbs2-0002" title="AndersonSD , LambertS , BrannanJD , WoodRJ , KoskelaH , MortonAR , et al. Laboratory protocol for exercise asthma to evaluate salbutamol given by two devices. Medicine &amp; Science in Sports &amp; Exercise2001;33(6):893‐900. ">Anderson 2001 Salb MDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol diskus 200 mcg</p> <p>Salbutamol MDI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 min</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0003" title="BlakeK , PearlmanDS , ScottC , WangY , StahlE , ArledgeT . Prevention of exercise‐induced bronchospasm in pediatric asthma patients: a comparison of salmeterol powder with albuterol. Annals of Allergy, Asthma &amp; Immunology1999;82(2):205‐11. ">Blake 1999 Salb 180</a> </p> <p><a href="./references#CD003564-bbs2-0004" title="BlakeK , PearlmanDS , ScottC , WangY , StahlE , ArledgeT . Prevention of exercise‐induced bronchospasm in pediatric asthma patients: a comparison of salmeterol powder with albuterol. Annals of Allergy, Asthma &amp; Immunology1999;82(2):205‐11. ">Blake 1999 Salm 25</a> </p> <p><a href="./references#CD003564-bbs2-0005" title="BlakeK , PearlmanDS , ScottC , WangY , StahlE , ArledgeT . Prevention of exercise‐induced bronchospasm in pediatric asthma patients: a comparison of salmeterol powder with albuterol. Annals of Allergy, Asthma &amp; Immunology1999;82(2):205‐11. ">Blake 1999 Salm 50</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Albuterol 180 mcg</p> <p>Salmeterol diskus 25 mcg</p> <p>Salmeterol diskus 50 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 min, 5 h 30, 11 h 30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0007" title="BonerAL , SpeziaE , PiovesanP , ChioccaE , MaiocchiG . Inhaled formoterol in the prevention of exercise‐induced bronchoconstriction in asthmatic children. American Journal of Respiratory and Critical Care Medicine1994;149(4):935‐9. ">Boner 1994 Salb 200</a> </p> <p><a href="./references#CD003564-bbs2-0006" title="BonerAL , SpeziaE , PiovesanP , ChioccaE , MaiocchiG . Inhaled formoterol in the prevention of exercise‐induced bronchoconstriction in asthmatic children. American Journal of Respiratory and Critical Care Medicine1994;149(4):935‐9. ">Boner 1994 Form 12</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol 200 mcg</p> <p>Formoterol 12 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 h, 12 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0008" title="BouletLP , TurcotteH , TenninaS . Comparative efficacy of salbutamol, ipratropium, and cromoglycate in the prevention of bronchospasm induced by exercise and hyperosmolar challenges. Journal of Allergy and Clinical Immunology1989;83(5):882‐7. ">Boulet 1989 Salb</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol 200 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 min</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0009" title="BronskyEA , SpectorSL , PearlmanDS , JustusSE , BishopAL . Albuterol aerosol versus albuterol Rotacaps in exercise‐induced bronchospasm in children. Journal of Asthma1995;32(3):207‐14. ">Bronski 1995 Salb MDI</a> </p> <p><a href="./references#CD003564-bbs2-0010" title="BronskyEA , SpectorSL , PearlmanDS , JustusSE , BishopAL . Albuterol aerosol versus albuterol Rotacaps in exercise‐induced bronchospasm in children. Journal of Asthma1995;32(3):207‐14. ">Bronski 1995 Salb Pwd</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Albuterol MDI 180 mcg</p> <p>Albuterol rotacaps 200 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 min</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0011" title="BronskyEA , PearlmanDS , PobinerBF , ScottC , WangY , StahlE . Prevention of exercise‐induced bronchospasm in pediatric asthma patients: a comparison of two salmeterol powder delivery devices. Pediatrics1999;104:501‐6. ">Bronski 1999 Salm Disk</a> </p> <p><a href="./references#CD003564-bbs2-0012" title="BronskyEA , PearlmanDS , PobinerBF , ScottC , WangY , StahlE . Prevention of exercise‐induced bronchospasm in pediatric asthma patients: a comparison of two salmeterol powder delivery devices. Pediatrics1999;104:501‐6. ">Bronski 1999 Salm Diskhal</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmetrol discus 50 mcg</p> <p>Salmeterol diskhaler 50 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 min, 5 h 30, 11 h 30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0015" title="BronskyEA , YegenU , YehCM , LarsenLV , Della CioppaG . Formoterol provides long‐lasting protection against exercise‐induced bronchospasm. Annals of Allergy, Asthma &amp; Immunology2002;89(4):407‐12. ">Bronski 2002 Salb</a> </p> <p><a href="./references#CD003564-bbs2-0013" title="BronskyEA , YegenU , YehCM , LarsenLV , Della CioppaG . Formoterol provides long‐lasting protection against exercise‐induced bronchospasm. Annals of Allergy, Asthma &amp; Immunology2002;89(4):407‐12. ">Bronski 2002 Form 12</a> </p> <p><a href="./references#CD003564-bbs2-0014" title="BronskyEA , YegenU , YehCM , LarsenLV , Della CioppaG . Formoterol provides long‐lasting protection against exercise‐induced bronchospasm. Annals of Allergy, Asthma &amp; Immunology2002;89(4):407‐12. ">Bronski 2002 Form 24</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Albuterol 180 mcg</p> <p>Formoterol 12 mcg</p> <p>Formoterol 24 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 min, 4 h, 8 h, 12 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0016" title="CarlsenKH , RoksundO , OlsholtK , NjåF , LeegaardJ , BrattenG . Overnight protection by inhaled salmeterol on exercise‐induced asthma in children. European Respiratory Journal1995;8(11):1852‐5. ">Carlsen 1995 Salm 25</a> </p> <p><a href="./references#CD003564-bbs2-0017" title="CarlsenKH , RoksundO , OlsholtK , NjåF , LeegaardJ , BrattenG . Overnight protection by inhaled salmeterol on exercise‐induced asthma in children. European Respiratory Journal1995;8(11):1852‐5. ">Carlsen 1995 Salm 50</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmeterol diskhaler 25 mcg</p> <p>Salmeterol diskhaler 50 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10‐12 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0019" title="CavagniG , CaffarelliC , ManniPL , StapaneI , PretiPAM , CantiniL . Salbutamol administered through a new spacer device to prevent exercise‐induced asthma. Advanced Therapy1993;10(5):207‐16. ">Cavagni 1993 Salb MDI</a> </p> <p><a href="./references#CD003564-bbs2-0018" title="CavagniG , CaffarelliC , ManniPL , StapaneI , PretiPAM , CantiniL . Salbutamol administered through a new spacer device to prevent exercise‐induced asthma. Advanced Therapy1993;10(5):207‐16. ">Cavagni 1993 Salb Jet</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol MDI 200 mcg</p> <p>Salbutamol jet disposable 200 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 min</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0020" title="ClarkePS , RatowskyDA . Effect of fenoterol hydrobromide and sodium cromoglycate individually and in combination on postexercise asthma. Annals of Allergy1990;64:187‐90. ">Clarke 1990 Fen</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fenoterol 100 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 min</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0022" title="DaugbjergP , NielsenKG , SkovM , BisgaardH . Duration of action of formoterol and salbutamol dry‐powder inhalation in prevention of exercise‐induced asthma in children. Acta Paediatrica1996;85(6):684‐7. ">Daugbjerg 1996 Salb</a> </p> <p><a href="./references#CD003564-bbs2-0021" title="DaugbjergP , NielsenKG , SkovM , BisgaardH . Duration of action of formoterol and salbutamol dry‐powder inhalation in prevention of exercise‐induced asthma in children. Acta Paediatrica1996;85(6):684‐7. ">Daugbjerg 1996 Form 12</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol 400 mcg</p> <p>Formoterol 12 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 h, 12 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0023" title="DebelicM , HertelG , KonigJ . Double‐blind crossover study comparing sodium cromoglycate, reproterol, reproterol plus sodium cromoglycate, and placebo in exercise‐induced asthma. Annals of Allergy1988;61(1):25‐9. ">Debelic 1988 Reproterol</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reproterol 1 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 min</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0024" title="deBenedictisFM , TuteriG , PazzelliP , NiccoliA , MezzettiD , VaccaroR . Salmeterol in exercise‐induced bronchoconstriction in asthmatic children: comparison of two doses. European Respiratory Journal1996;9(10):2099‐103. ">DeBenedictis 1996 Salm 25</a> </p> <p><a href="./references#CD003564-bbs2-0025" title="DeBenedictisFM , TuteriG , PazzelliP , NiccoliA , MezzettiD , VaccaroR . Salmeterol in exercise‐induced bronchoconstriction in asthmatic children: comparison of two doses. European Respiratory Journal1996;9(10):2099‐103. ">DeBenedictis 1996 Salm 50</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmeterol 25 mcg</p> <p>Salmeterol 50 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 h, 2 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0026" title="DeBenedictisFM , TuteriG , PazzelliP , SolinasLF , NiccoliA , ParenteC . Combination drug therapy for the prevention of exercise‐induced bronchoconstriction in children. Annals of Allergy, Asthma &amp; Immunology1998;80(4):352‐6. ">DeBenedictis 1998 Salb</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol 200 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 min</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0028" title="DelColG , SpeziaE , RichelliC , PiovesanP , CantiniL , BonerAL . Assessment of a new space device (Jet) for use with inhaled beta2‐agonists in children with exercise‐induced asthma. Pediatric Allergy and Immunology1993;7(2):119‐26. ">Del Col 1993 Salb MDI</a> </p> <p><a href="./references#CD003564-bbs2-0027" title="DelColG , SpeziaE , RichelliC , PiovesanP , CantiniL , BonerAL . Assessment of a new space device (Jet) for use with inhaled beta2‐agonists in children with exercise‐induced asthma. Pediatric Allergy and Immunology1993;7(2):119‐26. ">Del Col 1993 Salb Jet</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol MDI 200 mcg</p> <p>Salbutamol jet device 200 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 min</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0029" title="Dinh XuanAT , LebeauC , RocheR , FerriereA , ChaussainM . Inhaled terbutaline administered via a spacer fully prevents exercise‐induced asthma in young asthmatic subjects: a double‐blind, randomized, placebo‐controlled study. Journal of International Medical Research1989;17(6):506‐13. ">Dinh Xuan 1989 Terb</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terbutaline 500 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 min</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0030" title="EgglestonPA , BeasleyPP . Bronchodilation and inhibition of induced asthma by adrenergic agonists. Clinical Pharmacology &amp; Therapeutics1981;29(4):505‐510. ">Egglestone 1981 Terb 250</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terbutaline 250 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0031" title="FerrariM , BalestreriF , BaratieriS , BiasinC , OldaniV , Lo CascioV . Evidence of the rapid protective effect of formoterol dry‐powder inhalation against exercise‐induced bronchospasm in athletes with asthma. Respiration2000;67(5):510‐3. ">Ferrari 2000 Form 12</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Formoterol 12 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 min, 4 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0032" title="GarciaR , GuerraP , FeoF , GalindoPA , GómezE , BorjaJ , et al. Tachyphylaxis following regular use of formoterol in exercise‐induced bronchospasm. Journal of Investigational Allergology and Clinical Immunology2001;11(3):176‐82. ">Garcia 2001 Form 12</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Formoterol 12 mcg twice daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term (4 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 min, 12 h at days 1, 14 and 28</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0033" title="GreenCP , PriceJF . Prevention of exercise induced asthma by inhaled salmeterol xinafoate. Archives of Disease in Childhood1992;67(8):1014‐7. ">Green 1992 Salm 50</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmeterol 50 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 h, 5 h, 9 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0036" title="GronnerodTA , vonBergA , SchwabeG , SolimanS . Formoterol via Turbuhaler gave better protection than terbutaline against repeated exercise challenge for up to 12 hours in children and adolescents. Respiratory Medicine2000;94(7):661‐7. ">Gronnerod 2000 Terb 500</a> </p> <p><a href="./references#CD003564-bbs2-0035" title="GronnerodTA , vonBergA , SchwabeG , SolimanS . Formoterol via Turbuhaler gave better protection than terbutaline against repeated exercise challenge for up to 12 hours in children and adolescents. Respiratory Medicine2000;94(7):661‐7. ">Gronnerod 2000 Form 9</a> </p> <p><a href="./references#CD003564-bbs2-0034" title="GronnerodTA , vonBergA , SchwabeG , SolimanS . Formoterol via Turbuhaler gave better protection than terbutaline against repeated exercise challenge for up to 12 hours in children and adolescents. Respiratory Medicine2000;94(7):661‐7. ">Gronnerod 2000 Form 4.5</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terbutaline 500 mcg</p> <p>Formoterol 9 mcg</p> <p>Formoterol 4.5 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 min, 4 h, 8 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0037" title="HancoxRJ , SubbaraoP , KamadaD , WatsonRM , HargreaveFE , InmanMD . Beta2‐agonist tolerance and exercise‐induced bronchospasm. American Journal of Respiratory and Critical Care Medicine2002;165(8):1068‐70. ">Hancox 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol 800 mcg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term (1 week)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0038" title="HawksworthRJ , SykesAP , FarisM , MantT , LeeTH . Albuterol HFA is as effective as albuterol CFC in preventing exercise‐induced bronchoconstriction. Annals of Allergy, Asthma &amp; Immunology2002;88(5):473‐7. ">Hawksworth 2002 Salb HFA</a> </p> <p><a href="./references#CD003564-bbs2-0039" title="HawksworthRJ , SykesAP , FarisM , MantT , LeeTH . Albuterol HFA is as effective as albuterol CFC in preventing exercise‐induced bronchoconstriction. Annals of Allergy, Asthma &amp; Immunology2002;88(5):473‐7. ">Hawksworth 2002 Salb MDI</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol 180 HFA</p> <p>Salbutamol 180 mcg MDI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 min</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0040" title="HenriksenJM , DahlR . Effects of inhaled budesonide alone and in combination with low‐dose terbutaline in children with exercise‐induced asthma. American Review of Respiratory Disease1983;128(6):993‐7. ">Henricksen 1983 Terb</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terbutaline 32.5 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 min</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0041" title="HenriksenJM , AgertoftL , PedersenS . Protective effect and duration of action of inhaled formoterol and salbutamol on exercise‐induced asthma in children. Journal of Allergy and Clinical Immunology1992;89(6):1176‐82. ">Henricksen 1992 Salb</a> </p> <p><a href="./references#CD003564-bbs2-0042" title="HenriksenJM , AgertoftL , PedersenS . Protective effect and duration of action of inhaled formoterol and salbutamol on exercise‐induced asthma in children. Journal of Allergy and Clinical Immunology1992;89(6):1176‐82. ">Henriksen 1992 Form 12</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol 200 mcg</p> <p>Formoterol 12 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 min, 3 h, 5 h 30, 8 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0043" title="HillsEA , DaviesS , GearyM . Salmefamol and salbutamol in exercise‐induced asthma in children. British Journal of Diseases of the Chest1976;70(2):78‐82. ">Hills 1976 Salb</a> </p> <p><a href="./references#CD003564-bbs2-0044" title="HillsEA , DaviesS , GearyM . Salmefamol and salbutamol in exercise‐induced asthma in children. British Journal of Diseases of the Chest1976;70(2):78‐82. ">Hills 1976 Salmefamol</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol 200 mcg</p> <p>Salmefamol 200 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 min</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0045" title="InmanMD , O'ByrnePM . The effect of regular inhaled albuterol on exercise‐induced bronchoconstriction. American Journal of Respiratory and Critical Care Medicine1996;153(1):65‐9. ">Inman 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol 800 mcg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term (81 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0046" title="KempJP , DockhornRJ , BusseWW , BleeckerER , VanAsA . Prolonged effect of inhaled salmeterol against exercise‐induced bronchospasm. American Journal of Respiratory and Critical Care Medicine 94;150:1612‐5. ">Kemp 1994 Salb</a> </p> <p><a href="./references#CD003564-bbs2-0047" title="KempJP , DockhornRJ , BusseWW , BleeckerER , VanAsA . Prolonged effect of inhaled salmeterol against exercise‐induced bronchospasm. American Journal of Respiratory and Critical Care Medicine 94;150:1612‐5. ">Kemp 1994 Salm 42</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol 180 mcg</p> <p>Salmeterol 42 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 min, 5 h 30, 11 h 30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0048" title="KonigP , EgglestonPA , SerbyCW . Comparison of oral and inhaled metaproterenol for prevention of exercise‐induced asthma. Clinical Allergy1981;11(6):597‐604. ">Konig 1981 Metaprot</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metaproterenol 130 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 min, 1 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0051" title="LarssonK . Oxitropium bromide, ipratropium bromide and fenoterol in exercise‐induced asthma. Respiration1982;43(1):57‐63. ">Larsson 1982 Fen</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fenoterol 400 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 min</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0053" title="McAlpineLG , ThomsonNC . Prophylaxis of exercise‐induced asthma with inhaled formoterol, a long‐acting beta 2‐adrenergic agonist. Respiratory Medicine1990;84(4):293‐5. ">McAlpine 1990 Salb</a> </p> <p><a href="./references#CD003564-bbs2-0052" title="McAlpineLG , ThomsonNC . Prophylaxis of exercise‐induced asthma with inhaled formoterol, a long‐acting beta 2‐adrenergic agonist. Respiratory Medicine1990;84(4):293‐5. ">McAlpine 1990 Form 12</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol 200 mcg</p> <p>Formoterol 12 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 h, 4 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0054" title="McFaddenERJr , MillsR . Prevention of exercise‐induced bronchospasm with aerosolized albuterol. Current Therapeutic Research, Clinical and Experimental1986;39(1):112‐8. ">McFadden 1986 Salb (I)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol 200 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 min</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0055" title="McFaddenER , MillsR . Inhaled albuterol powder for the prevention of exercise‐induced bronchospasm. Immunology and Allergy Practice1986;8(6):199‐203. ">McFadden 1986 Salb (II)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol 180 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 min</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0056" title="MortonAR , ScottCA , FitchKD . Rimiterol and the prevention of exercise‐induced asthma. Journal of Allergy and Clinical Immunology1989;83(1):61‐5. ">Morton 1989 Rimet</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rimeterol 400 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 min</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0057" title="NelsonJA , StraussL , SkowronskiM , CiufoR , NovakR , McFaddenERJr . Effect of long‐term salmeterol treatment on exercise‐induced asthma. New England Journal of Medicine1998;339(3):141‐6. ">Nelson 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmeterol 84 mcg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term (29 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 min, 9 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0058" title="NewnhamDM , IngramCG , EarnshawJ , PalmerJB , DhillonDP . Salmeterol provides prolonged protection against exercise‐induced bronchoconstriction in a majority of subjects with mild, stable asthma. Respiratory Medicine1993;87(6):439‐4. ">Newnham 1993 Salb 200</a> </p> <p><a href="./references#CD003564-bbs2-0059" title="NewnhamDM , IngramCG , EarnshawJ , PalmerJB , DhillonDP . Salmeterol provides prolonged protection against exercise‐induced bronchoconstriction in a majority of subjects with mild, stable asthma. Respiratory Medicine1993;87(6):439‐4. ">Newnham 1993 Salm 50</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol 200 mcg</p> <p>Salmeterol 50 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 h, 6 h, 12 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0060" title="PatelKR . Bronchodilator activity of a new inhaled beta2‐adrenoceptor agonist, tulobuterol, and its protective effect in exercise‐induced asthma. British Journal of Clinical Pharmacology1986;21(2):234‐7. ">Patel 1986 Salb 200</a> </p> <p><a href="./references#CD003564-bbs2-0061" title="PatelKR . Bronchodilator activity of a new inhaled beta2‐adrenoceptor agonist, tulobuterol, and its protective effect in exercise‐induced asthma. British Journal of Clinical Pharmacology1986;21(2):234‐7. ">Patel 1986 Tulob 200</a> </p> <p><a href="./references#CD003564-bbs2-0062" title="PatelKR . Bronchodilator activity of a new inhaled beta2‐adrenoceptor agonist, tulobuterol, and its protective effect in exercise‐induced asthma. British Journal of Clinical Pharmacology1986;21(2):234‐7. ">Patel 1986 Tulob 400</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol 200 mcg</p> <p>Tolobuterol 200 mcg</p> <p>Tolobuterol 400 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 min</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0064" title="PatessioA , PoddaA , CaroneM , TrombettaN , DonnerCF . Protective effect and duration of action of formoterol aerosol on exercise‐induced asthma. European Respiratory Journal1991;4(3):296‐300. ">Patessio 1991 Salb 200</a> </p> <p><a href="./references#CD003564-bbs2-0063" title="PatessioA , PoddaA , CaroneM , TrombettaN , DonnerCF . Protective effect and duration of action of formoterol aerosol on exercise‐induced asthma. European Respiratory Journal1991;4(3):296‐300. ">Patessio 1991 Form 24</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol 200 mcg</p> <p>Formoterol 24 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 h, 8 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0067" title="PearlmanD , MilgromH , TillD , ZiehmerB . Effect of formoterol fumarate treatment on exercise‐induced bronchoconstriction in children. Annals of Allergy, Asthma &amp; Immunology2006;97(3):382‐8. ">Pearlman 2006 Salb 180</a> </p> <p><a href="./references#CD003564-bbs2-0065" title="PearlmanD , MilgromH , TillD , ZiehmerB . Effect of formoterol fumarate treatment on exercise‐induced bronchoconstriction in children. Annals of Allergy, Asthma &amp; Immunology2006;97(3):382‐8. ">Pearlman 2006 Form 12</a> </p> <p><a href="./references#CD003564-bbs2-0066" title="PearlmanD , MilgromH , TillD , ZiehmerB . Effect of formoterol fumarate treatment on exercise‐induced bronchoconstriction in children. Annals of Allergy, Asthma &amp; Immunology2006;97(3):382‐8. ">Pearlman 2006 Form 24</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol 180 mcg</p> <p>Formoterol 12 mcg</p> <p>Formoterol 24 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 min, 4 h, 8 h, 12 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0068" title="PearlmanDS , ReesW , SchaeferK , HuangH , AndrewsWT . An evaluation of levalbuterol HFA in the prevention of exercise‐induced bronchospasm. Journal of Asthma2007;44(9):729‐33. ">Pearlman 2007 Salb 90</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol 90 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 min</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0069" title="PhilipG , PearlmanDS , VillaránC , LegrandC , LoeysT , LangdonRB , et al. Single‐dose montelukast or salmeterol as protection against exercise‐induced bronchoconstriction. Chest2007;132(3):875‐83. ">Philip 2007 Salm 50</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmeterol 50 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 h, 8 h 30, 24 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0070" title="RamageL , LipworthBJ , IngramCG , CreeIA , DhillonDP . Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respiratory Medicine1994;88(5):363‐8. ">Ramage 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmeterol 100 mcg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term (28 days)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 h, 12 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0073" title="RichterK , JanickiS , JorresRA , MagnussenH . Acute protection against exercise‐induced bronchoconstriction by formoterol, salmeterol and terbutaline. European Respiratory Journal2002;19(5):865‐71. ">Richter 2002 Terb 500</a> </p> <p><a href="./references#CD003564-bbs2-0071" title="RichterK , JanickiS , JorresRA , MagnussenH . Acute protection against exercise‐induced bronchoconstriction by formoterol, salmeterol and terbutaline. European Respiratory Journal2002;19(5):865‐71. ">Richter 2002 Form 12</a> </p> <p><a href="./references#CD003564-bbs2-0072" title="RichterK , JanickiS , JorresRA , MagnussenH . Acute protection against exercise‐induced bronchoconstriction by formoterol, salmeterol and terbutaline. European Respiratory Journal2002;19(5):865‐71. ">Richter 2002 Salm 50</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terbutaline 500 mcg</p> <p>Formoterol 12 mcg</p> <p>Salmeterol 50 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 min, 30 min, 1 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0212" title="ShapiroGS , YegenU , XiangJ , KottakisJ , Della CioppaG . A randomized, double‐blind, single‐dose, crossover clinical trial of the onset and duration of protection from exercise‐induced bronchoconstriction by formoterol and albuterol. Clinical Therapeutics2002;24(12):2077‐87. ">Shapiro 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol 180 mcg</p> <p>Formoterol 12 mcg</p> <p>Formoterol 24 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 min, 4 h, 8 h, 12 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0077" title="SimonsFE , GerstnerTV , CheangMS . Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise‐induced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics1997;99(5):655‐9. ">Simons 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmeterol 50 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term (28 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 h, 9 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0078" title="StelmachI , GrzelewskiT , MajakP , JerzynskaJ , StelmachW , KunaP . Effect of different antiasthmatic treatments on exercise‐induced bronchoconstriction in children with asthma. Journal of Allergy and Clinical Immunology2008;121(2):383‐9. ">Stelmach 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Formoterol 9 mcg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term (28 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 h, 9 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0079" title="StormsW , ChervinskyP , GhannamAF , BirdS , HustadCM , EdelmanJM , et al. A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge. Respiratory Medicine2004;98(11):1051‐62. ">Storms 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salmeterol 100 mcg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Long‐term (28 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 h, 9 h</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0080" title="SturaniC , SchiavinaM , TosiI , GunellaG . Comparison of inhaled fenoterol and salbutamol in the prevention of exercise‐induced asthma. European Journal of Respiratory Diseases1983;128(Suppl):526‐8. ">Sturani 1983 Fen 400</a> </p> <p><a href="./references#CD003564-bbs2-0081" title="SturaniC , SchiavinaM , TosiI , GunellaG . Comparison of inhaled fenoterol and salbutamol in the prevention of exercise‐induced asthma. European Journal of Respiratory Diseases1983;128:526‐8. ">Sturani 1983 Salb 200</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fenoterol 400 mcg</p> <p>Salbutamol 200 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 min</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0082" title="VanHaitsma TA ,  MickleboroughT , StagerJM , KocejaDM ,  LindleyMR , ChapmanR . Comparative effects of caffeine and albuterol on the bronchoconstrictor response to exercise in asthmatic athletes. International Journal of Sports Medicine2010;31(4):231‐6. ">VanHaitsma 2010 Salb</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol 180 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 min</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0083" title="VazquezC , FidalgoI , VirtoMC , LabayruMT , CasasC . Efficacy of disodium chromoglycate, salbutamol and ipratroprium bromide on inhibition of exercise induced bronchospasm. Anales Espanoles de Pediatria1984;20(8):756‐62. ">Vasquez 1984 Salb 400</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salbutamol 400 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 min</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0084" title="WalkerSB , BiermanCW , PiersonWE , ShapiroGG , FurukawaCT , MingoTS . Bitolterol mesylate in exercise‐induced asthma. Journal of Allergy and Clinical Immunology1986;77:32‐6. ">Walker 1986 Bitolterol</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bitolterol 1050 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 min</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003564-bbs2-0085" title="WoolleyM , AndersonSD , QuigleyBM . Duration of protective effect of terbutaline sulfate and cromolyn sodium alone and in combination on exercise‐induced asthma. Chest1990;97(1):39‐45. ">Wolley 1990 Terb 500</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Terbutaline 500 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 min, 2 h, 4 h, 6 h</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of study interventions</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/full#CD003564-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003564-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Beta2‐agonists versus placebo (single administration)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Maximal percentage fall in FEV<sub>1</sub> <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>799</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐17.67 [‐19.51, ‐15.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Number of participants with an FEV<sub>1</sub> fall &gt; 10% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>773</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.06, 0.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Number of participants with an FEV<sub>1</sub> fall &gt; 15% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.03, 0.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Number of participants with an FEV<sub>1</sub> fall &gt; 20% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1021</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.06, 0.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Maximal percentage fall in PEF <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐24.61 [‐37.57, ‐11.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Maximal percentage fall in FEF 25‐75 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐20.75 [‐27.17, ‐14.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Side effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.43, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Subgroup analysis: maximal percentage fall in FEV<sub>1</sub> SABA vs LABA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐17.67 [‐19.51, ‐15.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 SABA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐18.99 [‐21.38, ‐16.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 LABA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐15.60 [‐18.29, ‐12.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Subgroup analysis: maximal percentage fall in FEV<sub>1</sub>: salmeterol versus formoterol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐15.60 [‐18.29, ‐12.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Salmeterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐12.73 [‐16.10, ‐9.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Formoterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐18.24 [‐22.15, ‐14.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Subgroup analysis: maximal percentage fall in FEV<sub>1</sub>: adults versus children <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐16.75 [‐19.12, ‐14.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐18.77 [‐20.78, ‐16.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐15.32 [‐18.88, ‐11.75]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Beta2‐agonists versus placebo (single administration)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003564.pub3/references#CD003564-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003564.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD003564-note-0001">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003564-note-0003">فارسی</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003564\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003564\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003564\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003564\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003564\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003564\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003564\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003564\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003564\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003564\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003564\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003564\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003564\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003564\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003564\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003564\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003564\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003564\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=IYhCEbRn&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003564.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003564.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003564.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003564.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003564.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715043514"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003564.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715043518"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003564.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d7d724bf51bde',t:'MTc0MDcxNTA0My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 